#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-11	Integrative	_
1-2	12-27	Transcriptomics	_
1-3	28-35	Reveals	_
1-4	36-44	Sexually	_
1-5	45-54	Dimorphic	_
1-6	55-62	Control	_
1-7	63-65	of	_
1-8	66-69	the	_
1-9	70-91	Cholinergic/Neurokine	_
1-10	92-101	Interface	_
1-11	102-104	in	_
1-12	105-118	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-13	119-122	and	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-14	123-130	Bipolar	http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder
1-15	131-139	Disorder	http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder
1-16	140-147	Summary	_
1-17	148-151	RNA	_
1-18	152-162	sequencing	_
1-19	163-171	analyses	_
1-20	172-175	are	_
1-21	176-181	often	_
1-22	182-189	limited	_
1-23	190-192	to	_
1-24	193-204	identifying	_
1-25	205-211	lowest	_
1-26	212-213	p	_
1-27	214-219	value	_
1-28	220-231	transcripts	_
1-29	232-233	,	_
1-30	234-239	which	_
1-31	240-244	does	_
1-32	245-248	not	_
1-33	249-256	address	_
1-34	257-266	polygenic	_
1-35	267-276	phenomena	_
1-36	277-278	.	_

2-1	279-281	To	_
2-2	282-290	overcome	_
2-3	291-295	this	_
2-4	296-306	limitation	_
2-5	307-308	,	_
2-6	309-311	we	_
2-7	312-321	developed	_
2-8	322-324	an	_
2-9	325-336	integrative	_
2-10	337-345	approach	_
2-11	346-350	that	_
2-12	351-359	combines	_
2-13	360-371	large-scale	_
2-14	372-386	transcriptomic	_
2-15	387-400	meta-analysis	_
2-16	401-403	of	_
2-17	404-411	patient	_
2-18	412-417	brain	_
2-19	418-425	tissues	_
2-20	426-430	with	_
2-21	431-442	single-cell	_
2-22	443-453	sequencing	_
2-23	454-458	data	_
2-24	459-461	of	_
2-25	462-465	CNS	_
2-26	466-473	neurons	_
2-27	474-475	,	_
2-28	476-481	short	_
2-29	482-485	RNA	_
2-30	486-496	sequencing	_
2-31	497-499	of	_
2-32	500-505	human	_
2-33	506-511	male-	_
2-34	512-515	and	_
2-35	516-534	female-originating	_
2-36	535-539	cell	_
2-37	540-545	lines	_
2-38	546-547	,	_
2-39	548-551	and	_
2-40	552-564	connectomics	_
2-41	565-567	of	_
2-42	568-581	transcription	_
2-43	582-588	factor	_
2-44	589-592	and	_
2-45	593-601	microRNA	_
2-46	602-614	interactions	_
2-47	615-619	with	_
2-48	620-629	perturbed	_
2-49	630-641	transcripts	_
2-50	642-643	.	_

3-1	644-646	We	_
3-2	647-651	used	_
3-3	652-656	this	_
3-4	657-665	pipeline	_
3-5	666-668	to	_
3-6	669-676	analyze	_
3-7	677-685	cortical	_
3-8	686-697	transcripts	_
3-9	698-700	of	_
3-10	701-714	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-11	715-718	and	_
3-12	719-726	bipolar	_
3-13	727-735	disorder	_
3-14	736-744	patients	_
3-15	745-746	.	_

4-1	747-755	Although	_
4-2	756-761	these	_
4-3	762-773	pathologies	_
4-4	774-778	show	_
4-5	779-786	massive	_
4-6	787-802	transcriptional	_
4-7	803-812	parallels	_
4-8	813-814	,	_
4-9	815-820	their	_
4-10	821-831	clinically	_
4-11	832-842	well-known	_
4-12	843-849	sexual	_
4-13	850-861	dimorphisms	_
4-14	862-868	remain	_
4-15	869-880	unexplained	_
4-16	881-882	.	_

5-1	883-886	Our	_
5-2	887-893	method	_
5-3	894-901	reveals	_
5-4	902-905	the	_
5-5	906-917	differences	_
5-6	918-925	between	_
5-7	926-935	afflicted	_
5-8	936-939	men	_
5-9	940-943	and	_
5-10	944-949	women	_
5-11	950-953	and	_
5-12	954-964	identifies	_
5-13	965-981	disease-affected	_
5-14	982-990	pathways	_
5-15	991-993	of	_
5-16	994-1005	cholinergic	_
5-17	1006-1018	transmission	_
5-18	1019-1022	and	_
5-19	1023-1035	gp130-family	_
5-20	1036-1045	neurokine	_
5-21	1046-1057	controllers	_
5-22	1058-1060	of	_
5-23	1061-1067	immune	_
5-24	1068-1076	function	_
5-25	1077-1088	interlinked	_
5-26	1089-1091	by	_
5-27	1092-1101	microRNAs	_
5-28	1102-1103	.	_

6-1	1104-1108	This	_
6-2	1109-1117	approach	_
6-3	1118-1121	may	_
6-4	1122-1126	open	_
6-5	1127-1137	additional	_
6-6	1138-1150	perspectives	_
6-7	1151-1154	for	_
6-8	1155-1162	seeking	_
6-9	1163-1173	biomarkers	_
6-10	1174-1177	and	_
6-11	1178-1189	therapeutic	_
6-12	1190-1197	targets	_
6-13	1198-1200	in	_
6-14	1201-1206	other	_
6-15	1207-1218	transmitter	_
6-16	1219-1226	systems	_
6-17	1227-1230	and	_
6-18	1231-1239	diseases	_
6-19	1240-1241	.	_

7-1	1242-1251	Graphical	_
7-2	1252-1260	Abstract	_
7-3	1261-1271	Highlights	_
7-4	1272-1283	Single-cell	_
7-5	1284-1298	transcriptomes	_
7-6	1299-1305	reveal	_
7-7	1306-1307	a	_
7-8	1308-1314	unique	_
7-9	1315-1322	profile	_
7-10	1323-1325	of	_
7-11	1326-1334	cortical	_
7-12	1335-1346	cholinergic	_
7-13	1347-1354	neurons	_
7-14	1355-1362	Female-	_
7-15	1363-1366	and	_
7-16	1367-1379	male-derived	_
7-17	1380-1385	cells	_
7-18	1386-1390	show	_
7-19	1391-1399	distinct	_
7-20	1400-1417	neurokine-induced	_
7-21	1418-1423	miRNA	_
7-22	1424-1433	responses	_
7-23	1434-1448	Differentially	_
7-24	1449-1457	enriched	_
7-25	1458-1466	microRNA	_
7-26	1467-1475	families	_
7-27	1476-1486	constitute	_
7-28	1487-1488	a	_
7-29	1489-1504	self-organizing	_
7-30	1505-1512	network	_
7-31	1513-1524	Integrative	_
7-32	1525-1533	analysis	_
7-33	1534-1544	identifies	_
7-34	1545-1559	mir-10/mir-199	_
7-35	1560-1570	regulators	_
7-36	1571-1573	of	_
7-37	1574-1585	cholinergic	_
7-38	1586-1594	function	_
7-39	1595-1606	Lobentanzer	_
7-40	1607-1609	et	_
7-41	1610-1612	al	_
7-42	1613-1614	.	_

8-1	1615-1619	show	_
8-2	1620-1623	how	_
8-3	1624-1641	bioinformatically	_
8-4	1642-1651	supported	_
8-5	1652-1667	high-throughput	_
8-6	1668-1678	techniques	_
8-7	1679-1683	such	_
8-8	1684-1686	as	_
8-9	1687-1692	short	_
8-10	1693-1696	RNA	_
8-11	1697-1707	sequencing	_
8-12	1708-1711	can	_
8-13	1712-1718	bridge	_
8-14	1719-1722	the	_
8-15	1723-1726	gap	_
8-16	1727-1734	between	_
8-17	1735-1746	traditional	_
8-18	1747-1756	molecular	_
8-19	1757-1768	interaction	_
8-20	1769-1776	studies	_
8-21	1777-1780	and	_
8-22	1781-1787	purely	_
8-23	1788-1801	bioinformatic	_
8-24	1802-1812	prediction	_
8-25	1813-1822	paradigms	_
8-26	1823-1825	in	_
8-27	1826-1828	an	_
8-28	1829-1836	example	_
8-29	1837-1844	focused	_
8-30	1845-1847	on	_
8-31	1848-1861	disentangling	_
8-32	1862-1865	the	_
8-33	1866-1872	sexual	_
8-34	1873-1883	dimorphism	_
8-35	1884-1886	in	_
8-36	1887-1895	microRNA	_
8-37	1896-1906	regulation	_
8-38	1907-1909	of	_
8-39	1910-1913	the	_
8-40	1914-1935	cholinergic/neurokine	_
8-41	1936-1945	interface	_
8-42	1946-1948	in	_
8-43	1949-1955	mental	_
8-44	1956-1965	disorders	_
8-45	1966-1967	.	_

9-1	1968-1980	STAR★Methods	_
9-2	1981-1984	Key	_
9-3	1985-1994	Resources	_
9-4	1995-2000	Table	_
9-5	2001-2005	Lead	_
9-6	2006-2013	Contact	_
9-7	2014-2017	and	_
9-8	2018-2027	Materials	_
9-9	2028-2040	Availability	_
9-10	2041-2048	Further	_
9-11	2049-2060	information	_
9-12	2061-2064	and	_
9-13	2065-2073	requests	_
9-14	2074-2077	for	_
9-15	2078-2087	resources	_
9-16	2088-2091	and	_
9-17	2092-2100	reagents	_
9-18	2101-2107	should	_
9-19	2108-2110	be	_
9-20	2111-2119	directed	_
9-21	2120-2122	to	_
9-22	2123-2126	and	_
9-23	2127-2131	will	_
9-24	2132-2134	be	_
9-25	2135-2144	fulfilled	_
9-26	2145-2147	by	_
9-27	2148-2151	the	_
9-28	2152-2156	Lead	_
9-29	2157-2164	Contact	_
9-30	2165-2166	,	_
9-31	2167-2174	Hermona	_
9-32	2175-2180	Soreq	_
9-33	2181-2182	(	_
9-34	2183-2196	hermona.soreq	_
9-35	2197-2198	@	_
9-36	2199-2214	mail.huji.ac.il	_
9-37	2215-2216	)	_
9-38	2217-2218	.	_

10-1	2219-2223	This	_
10-2	2224-2229	study	_
10-3	2230-2233	did	_
10-4	2234-2237	not	_
10-5	2238-2246	generate	_
10-6	2247-2250	new	_
10-7	2251-2257	unique	_
10-8	2258-2266	reagents	_
10-9	2267-2268	.	_

11-1	2269-2281	Experimental	_
11-2	2282-2287	Model	_
11-3	2288-2291	and	_
11-4	2292-2299	Subject	_
11-5	2300-2307	Details	_
11-6	2308-2312	Cell	_
11-7	2313-2318	Lines	_
11-8	2319-2321	We	_
11-9	2322-2330	employed	_
11-10	2331-2337	LA-N-2	_
11-11	2338-2339	(	_
11-12	2340-2346	female	_
11-13	2347-2348	)	_
11-14	2349-2350	(	_
11-15	2351-2355	DSMZ	_
11-16	2356-2359	Cat	_
11-17	2360-2361	#	_
11-18	2362-2369	ACC-671	_
11-19	2370-2371	,	_
11-20	2372-2376	RRID	_
11-21	2377-2378	:	_
11-22	2379-2388	CVCL_1829	_
11-23	2389-2390	)	_
11-24	2391-2394	and	_
11-25	2395-2401	LA-N-5	_
11-26	2402-2403	(	_
11-27	2404-2408	male	_
11-28	2409-2410	)	_
11-29	2411-2412	(	_
11-30	2413-2417	DSMZ	_
11-31	2418-2421	Cat	_
11-32	2422-2423	#	_
11-33	2424-2431	ACC-673	_
11-34	2432-2433	,	_
11-35	2434-2438	RRID	_
11-36	2439-2440	:	_
11-37	2441-2450	CVCL_0389	_
11-38	2451-2452	)	_
11-39	2453-2458	cells	_
11-40	2459-2461	as	_
11-41	2462-2465	our	_
11-42	2466-2470	main	_
11-43	2471-2483	experimental	_
11-44	2484-2489	model	_
11-45	2490-2496	system	_
11-46	2497-2498	.	_

12-1	2499-2502	The	_
12-2	2503-2508	cells	_
12-3	2509-2513	were	_
12-4	2514-2523	purchased	_
12-5	2524-2526	at	_
12-6	2527-2531	DSMZ	_
12-7	2532-2533	(	_
12-8	2534-2546	Braunschweig	_
12-9	2547-2548	,	_
12-10	2549-2556	Germany	_
12-11	2557-2558	)	_
12-12	2559-2560	.	_

13-1	2561-2566	These	_
13-2	2567-2572	cells	_
13-3	2573-2580	respond	_
13-4	2581-2583	to	_
13-5	2584-2599	differentiation	_
13-6	2600-2602	by	_
13-7	2603-2610	several	_
13-8	2611-2621	neurokines	_
13-9	2622-2623	(	_
13-10	2624-2628	CNTF	_
13-11	2629-2630	,	_
13-12	2631-2634	LIF	_
13-13	2635-2636	,	_
13-14	2637-2641	IL-6	_
13-15	2642-2643	)	_
13-16	2644-2646	by	_
13-17	2647-2658	cholinergic	_
13-18	2659-2674	differentiation	_
13-19	2675-2688	corresponding	_
13-20	2689-2693	with	_
13-21	2694-2703	elevation	_
13-22	2704-2706	of	_
13-23	2707-2714	choline	_
13-24	2715-2732	acetyltransferase	_
13-25	2733-2734	(	_
13-26	2735-2739	ChAT	_
13-27	2740-2741	)	_
13-28	2742-2743	,	_
13-29	2744-2747	the	_
13-30	2748-2755	central	_
13-31	2756-2767	cholinergic	_
13-32	2768-2774	marker	_
13-33	2775-2776	(	_
13-34	2777-2781	mRNA	_
13-35	2782-2783	,	_
13-36	2784-2791	protein	_
13-37	2792-2793	,	_
13-38	2794-2797	and	_
13-39	2798-2806	activity	_
13-40	2807-2808	)	_
13-41	2809-2811	as	_
13-42	2812-2816	well	_
13-43	2817-2819	as	_
13-44	2820-2823	its	_
13-45	2824-2832	intronic	_
13-46	2833-2842	vesicular	_
13-47	2843-2858	ACh-transporter	_
13-48	2859-2863	gene	_
13-49	2864-2865	,	_
13-50	2866-2871	vAChT	_
13-51	2872-2873	(	_
13-52	2874-2877	aka	_
13-53	2878-2885	SLC18A3	_
13-54	2886-2887	)	_
13-55	2888-2889	.	_

14-1	2890-2895	Cells	_
14-2	2896-2900	were	_
14-3	2901-2911	maintained	_
14-4	2912-2914	at	_
14-5	2915-2919	37°C	_
14-6	2920-2922	in	_
14-7	2923-2924	8	_
14-8	2925-2926	%	_
14-9	2927-2930	CO2	_
14-10	2931-2941	atmosphere	_
14-11	2942-2944	in	_
14-12	2945-2951	medium	_
14-13	2952-2962	consisting	_
14-14	2963-2965	of	_
14-15	2966-2969	1:1	_
14-16	2970-2974	DMEM	_
14-17	2975-2978	and	_
14-18	2979-2983	RPMI	_
14-19	2984-2988	1640	_
14-20	2989-2990	,	_
14-21	2991-2995	with	_
14-22	2996-2998	20	_
14-23	2999-3000	%	_
14-24	3001-3004	FCS	_
14-25	3005-3006	,	_
14-26	3007-3011	with	_
14-27	3012-3018	weekly	_
14-28	3019-3025	splits	_
14-29	3026-3027	.	_

15-1	3028-3039	Experiments	_
15-2	3040-3044	were	_
15-3	3045-3054	performed	_
15-4	3055-3062	between	_
15-5	3063-3069	splits	_
15-6	3070-3073	2-6	_
15-7	3074-3079	after	_
15-8	3080-3087	thawing	_
15-9	3088-3089	.	_

16-1	3090-3097	HEK293T	_
16-2	3098-3101	and	_
16-3	3102-3106	U937	_
16-4	3107-3112	cells	_
16-5	3113-3117	were	_
16-6	3118-3127	purchased	_
16-7	3128-3130	at	_
16-8	3131-3135	ATCC	_
16-9	3136-3139	and	_
16-10	3140-3150	maintained	_
16-11	3151-3160	according	_
16-12	3161-3163	to	_
16-13	3164-3168	ATCC	_
16-14	3169-3179	guidelines	_
16-15	3180-3181	.	_

17-1	3182-3193	Experiments	_
17-2	3194-3198	were	_
17-3	3199-3208	performed	_
17-4	3209-3216	between	_
17-5	3217-3223	splits	_
17-6	3224-3228	2-10	_
17-7	3229-3230	.	_

18-1	3231-3236	Human	_
18-2	3237-3244	Patient	_
18-3	3245-3249	Data	_
18-4	3250-3252	We	_
18-5	3253-3257	used	_
18-6	3258-3268	previously	_
18-7	3269-3278	published	_
18-8	3279-3287	datasets	_
18-9	3288-3291	for	_
18-10	3292-3299	several	_
18-11	3300-3308	analyses	_
18-12	3309-3310	.	_

19-1	3311-3316	These	_
19-2	3317-3325	comprise	_
19-3	3326-3333	several	_
19-4	3334-3342	cortical	_
19-5	3343-3351	datasets	_
19-6	3352-3354	in	_
19-7	3355-3358	raw	_
19-8	3359-3365	format	_
19-9	3366-3367	(	_
19-10	3368-3378	Affymetrix	_
19-11	3379-3380	)	_
19-12	3381-3385	from	_
19-13	3386-3390	NCBI	_
19-14	3391-3394	GEO	_
19-15	3395-3396	:	_
19-16	3397-3405	GSE35978	_
19-17	3406-3407	(	_
19-18	3408-3411	SCZ	_
19-19	3412-3413	&	_
19-20	3414-3416	BD	_
19-21	3417-3418	)	_
19-22	3419-3420	,	_
19-23	3421-3429	GSE53987	_
19-24	3430-3431	(	_
19-25	3432-3435	SCZ	_
19-26	3436-3437	&	_
19-27	3438-3440	BD	_
19-28	3441-3442	)	_
19-29	3443-3444	,	_
19-30	3445-3453	GSE12649	_
19-31	3454-3455	(	_
19-32	3456-3459	SCZ	_
19-33	3460-3461	&	_
19-34	3462-3464	BD	_
19-35	3465-3466	)	_
19-36	3467-3468	,	_
19-37	3469-3477	GSE17612	_
19-38	3478-3479	(	_
19-39	3480-3483	SCZ	_
19-40	3484-3485	)	_
19-41	3486-3487	,	_
19-42	3488-3496	GSE21138	_
19-43	3497-3498	(	_
19-44	3499-3502	SCZ	_
19-45	3503-3504	)	_
19-46	3505-3506	,	_
19-47	3507-3514	GSE5392	_
19-48	3515-3516	(	_
19-49	3517-3519	BD	_
19-50	3520-3521	)	_
19-51	3522-3523	;	_
19-52	3524-3539	next-generation	_
19-53	3540-3550	sequencing	_
19-54	3551-3555	from	_
19-55	3556-3560	NCBI	_
19-56	3561-3564	GEO	_
19-57	3565-3566	:	_
19-58	3567-3575	GSE80655	_
19-59	3576-3577	,	_
19-60	3578-3587	GSE106589	_
19-61	3588-3589	,	_
19-62	3590-3598	GSE68559	_
19-63	3599-3600	,	_
19-64	3601-3609	GSE96659	_
19-65	3610-3611	,	_
19-66	3612-3620	GSE45642	_
19-67	3621-3622	;	_
19-68	3623-3627	data	_
19-69	3628-3630	of	_
19-70	3631-3636	DLPFC	_
19-71	3637-3647	sequencing	_
19-72	3648-3650	of	_
19-73	3651-3654	600	_
19-74	3655-3658	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
19-75	3659-3667	patients	_
19-76	3668-3671	and	_
19-77	3672-3680	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
19-78	3681-3684	was	_
19-79	3685-3693	obtained	_
19-80	3694-3698	from	_
19-81	3699-3702	the	_
19-82	3703-3709	Common	_
19-83	3710-3714	Mind	_
19-84	3715-3725	Consortium	_
19-85	3726-3727	(	_
19-86	3728-3732	http	_
19-87	3733-3734	:	_
19-88	3735-3756	//www.synapse.org/CMC	_
19-89	3757-3758	)	_
19-90	3759-3760	.	_

20-1	3761-3767	Method	_
20-2	3768-3775	Details	_
20-3	3776-3790	Methodological	_
20-4	3791-3798	Outline	_
20-5	3799-3807	Focusing	_
20-6	3808-3810	on	_
20-7	3811-3812	a	_
20-8	3813-3825	well-defined	_
20-9	3826-3829	set	_
20-10	3830-3832	of	_
20-11	3833-3838	genes	_
20-12	3839-3843	aims	_
20-13	3844-3846	to	_
20-14	3847-3852	avoid	_
20-15	3853-3857	some	_
20-16	3858-3860	of	_
20-17	3861-3864	the	_
20-18	3865-3869	data	_
20-19	3870-3874	loss	_
20-20	3875-3879	that	_
20-21	3880-3886	occurs	_
20-22	3887-3891	when	_
20-23	3892-3899	patient	_
20-24	3900-3907	tissues	_
20-25	3908-3918	comprising	_
20-26	3919-3927	multiple	_
20-27	3928-3932	cell	_
20-28	3933-3938	types	_
20-29	3939-3942	are	_
20-30	3943-3954	homogenized	_
20-31	3955-3958	for	_
20-32	3959-3967	analysis	_
20-33	3968-3969	.	_

21-1	3970-3974	This	_
21-2	3975-3977	is	_
21-3	3978-3990	particularly	_
21-4	3991-3999	relevant	_
21-5	4000-4003	for	_
21-6	4004-4012	cortical	_
21-7	4013-4024	cholinergic	_
21-8	4025-4037	interneurons	_
21-9	4038-4039	,	_
21-10	4040-4045	where	_
21-11	4046-4049	the	_
21-12	4050-4054	cell	_
21-13	4055-4059	type	_
21-14	4060-4062	of	_
21-15	4063-4071	interest	_
21-16	4072-4074	is	_
21-17	4075-4086	numerically	_
21-18	4087-4095	inferior	_
21-19	4096-4097	,	_
21-20	4098-4101	and	_
21-21	4102-4116	transcriptomic	_
21-22	4117-4121	data	_
21-23	4122-4125	can	_
21-24	4126-4128	be	_
21-25	4129-4130	“	_
21-26	4131-4138	diluted	_
21-27	4139-4140	”	_
21-28	4141-4143	by	_
21-29	4144-4147	the	_
21-30	4148-4153	other	_
21-31	4154-4155	,	_
21-32	4156-4160	more	_
21-33	4161-4170	prominent	_
21-34	4171-4175	cell	_
21-35	4176-4181	types	_
21-36	4182-4183	,	_
21-37	4184-4188	such	_
21-38	4189-4191	as	_
21-39	4192-4196	glia	_
21-40	4197-4199	or	_
21-41	4200-4210	astrocytes	_
21-42	4211-4212	.	_

22-1	4213-4216	The	_
22-2	4217-4227	consequent	_
22-3	4228-4236	increase	_
22-4	4237-4239	in	_
22-5	4240-4249	detection	_
22-6	4250-4259	threshold	_
22-7	4260-4263	can	_
22-8	4264-4266	be	_
22-9	4267-4277	re-lowered	_
22-10	4278-4280	by	_
22-11	4281-4289	reducing	_
22-12	4290-4293	the	_
22-13	4294-4300	number	_
22-14	4301-4303	of	_
22-15	4304-4309	genes	_
22-16	4310-4316	tested	_
22-17	4317-4318	.	_

23-1	4319-4327	Analysis	_
23-2	4328-4330	of	_
23-3	4331-4337	single	_
23-4	4338-4342	cell	_
23-5	4343-4351	datasets	_
23-6	4352-4355	can	_
23-7	4356-4365	ascertain	_
23-8	4366-4370	that	_
23-9	4371-4374	the	_
23-10	4375-4380	genes	_
23-11	4381-4389	analyzed	_
23-12	4390-4393	are	_
23-13	4394-4408	representative	_
23-14	4409-4412	and	_
23-15	4413-4419	fairly	_
23-16	4420-4426	unique	_
23-17	4427-4429	to	_
23-18	4430-4433	the	_
23-19	4434-4438	cell	_
23-20	4439-4443	type	_
23-21	4444-4446	in	_
23-22	4447-4455	question	_
23-23	4456-4457	,	_
23-24	4458-4460	as	_
23-25	4461-4464	was	_
23-26	4465-4468	the	_
23-27	4469-4473	case	_
23-28	4474-4477	for	_
23-29	4478-4489	cholinergic	_
23-30	4490-4497	markers	_
23-31	4498-4500	in	_
23-32	4501-4504	our	_
23-33	4505-4510	study	_
23-34	4511-4512	,	_
23-35	4513-4516	and	_
23-36	4517-4523	utmost	_
23-37	4524-4528	care	_
23-38	4529-4535	should	_
23-39	4536-4538	be	_
23-40	4539-4544	taken	_
23-41	4545-4548	for	_
23-42	4549-4552	any	_
23-43	4553-4557	gene	_
23-44	4558-4561	set	_
23-45	4562-4564	of	_
23-46	4565-4573	interest	_
23-47	4574-4577	and	_
23-48	4578-4581	any	_
23-49	4582-4586	kind	_
23-50	4587-4589	of	_
23-51	4590-4596	tissue	_
23-52	4597-4606	subjected	_
23-53	4607-4609	to	_
23-54	4610-4614	this	_
23-55	4615-4619	kind	_
23-56	4620-4622	of	_
23-57	4623-4631	analysis	_
23-58	4632-4633	.	_

24-1	4634-4637	Our	_
24-2	4638-4646	approach	_
24-3	4647-4649	is	_
24-4	4650-4655	based	_
24-5	4656-4658	on	_
24-6	4659-4662	the	_
24-7	4663-4675	availability	_
24-8	4676-4678	of	_
24-9	4679-4687	suitable	_
24-10	4688-4695	amounts	_
24-11	4696-4698	of	_
24-12	4699-4706	patient	_
24-13	4707-4711	data	_
24-14	4712-4714	in	_
24-15	4715-4728	web-available	_
24-16	4729-4733	form	_
24-17	4734-4735	,	_
24-18	4736-4744	combined	_
24-19	4745-4749	with	_
24-20	4750-4751	a	_
24-21	4752-4764	standardized	_
24-22	4765-4773	pipeline	_
24-23	4774-4776	of	_
24-24	4777-4788	statistical	_
24-25	4789-4803	pre-processing	_
24-26	4804-4806	to	_
24-27	4807-4818	equilibrate	_
24-28	4819-4829	individual	_
24-29	4830-4841	statistical	_
24-30	4842-4852	influences	_
24-31	4853-4854	.	_

25-1	4855-4865	Regardless	_
25-2	4866-4868	of	_
25-3	4869-4872	how	_
25-4	4873-4880	patient	_
25-5	4881-4885	data	_
25-6	4886-4889	and	_
25-7	4890-4893	the	_
25-8	4894-4900	subset	_
25-9	4901-4903	of	_
25-10	4904-4909	genes	_
25-11	4910-4912	of	_
25-12	4913-4921	interest	_
25-13	4922-4925	are	_
25-14	4926-4934	selected	_
25-15	4935-4936	,	_
25-16	4937-4940	the	_
25-17	4941-4950	reduction	_
25-18	4951-4953	in	_
25-19	4954-4960	number	_
25-20	4961-4963	of	_
25-21	4964-4972	analyzed	_
25-22	4973-4978	genes	_
25-23	4979-4982	has	_
25-24	4983-4985	to	_
25-25	4986-4988	be	_
25-26	4989-4998	performed	_
25-27	4999-5004	after	_
25-28	5005-5016	application	_
25-29	5017-5019	of	_
25-30	5020-5023	the	_
25-31	5024-5030	linear	_
25-32	5031-5036	model	_
25-33	5037-5039	to	_
25-34	5040-5043	the	_
25-35	5044-5050	batch-	_
25-36	5051-5054	and	_
25-37	5055-5074	covariate-corrected	_
25-38	5075-5079	data	_
25-39	5080-5082	to	_
25-40	5083-5088	avoid	_
25-41	5089-5101	interference	_
25-42	5102-5106	with	_
25-43	5107-5114	correct	_
25-44	5115-5121	linear	_
25-45	5122-5132	regression	_
25-46	5133-5134	.	_

26-1	5135-5139	Once	_
26-2	5140-5143	the	_
26-3	5144-5154	expression	_
26-4	5155-5159	data	_
26-5	5160-5161	(	_
26-6	5162-5164	be	_
26-7	5165-5167	it	_
26-8	5168-5174	array-	_
26-9	5175-5177	or	_
26-10	5178-5196	sequencing-derived	_
26-11	5197-5198	)	_
26-12	5199-5202	has	_
26-13	5203-5207	been	_
26-14	5208-5217	corrected	_
26-15	5218-5221	for	_
26-16	5222-5227	batch	_
26-17	5228-5235	effects	_
26-18	5236-5239	and	_
26-19	5240-5250	covariates	_
26-20	5251-5252	,	_
26-21	5253-5256	and	_
26-22	5257-5265	outliers	_
26-23	5266-5270	have	_
26-24	5271-5275	been	_
26-25	5276-5283	removed	_
26-26	5284-5285	,	_
26-27	5286-5288	it	_
26-28	5289-5292	can	_
26-29	5293-5295	be	_
26-30	5296-5304	analyzed	_
26-31	5305-5309	with	_
26-32	5310-5311	a	_
26-33	5312-5320	suitable	_
26-34	5321-5333	differential	_
26-35	5334-5338	gene	_
26-36	5339-5349	expression	_
26-37	5350-5359	algorithm	_
26-38	5360-5361	.	_

27-1	5362-5365	The	_
27-2	5366-5375	resulting	_
27-3	5376-5377	,	_
27-4	5378-5388	individual	_
27-5	5389-5397	datasets	_
27-6	5398-5404	should	_
27-7	5405-5412	ideally	_
27-8	5413-5421	converge	_
27-9	5422-5424	on	_
27-10	5425-5432	similar	_
27-11	5433-5438	logFC	_
27-12	5439-5445	values	_
27-13	5446-5447	,	_
27-14	5448-5451	but	_
27-15	5452-5455	may	_
27-16	5456-5460	also	_
27-17	5461-5465	show	_
27-18	5466-5477	controversy	_
27-19	5478-5485	between	_
27-20	5486-5496	individual	_
27-21	5497-5508	experiments	_
27-22	5509-5510	,	_
27-23	5511-5516	which	_
27-24	5517-5520	can	_
27-25	5521-5527	result	_
27-26	5528-5532	from	_
27-27	5533-5534	a	_
27-28	5535-5544	multitude	_
27-29	5545-5547	of	_
27-30	5548-5555	factors	_
27-31	5556-5560	from	_
27-32	5561-5571	biological	_
27-33	5572-5579	variety	_
27-34	5580-5582	to	_
27-35	5583-5591	sampling	_
27-36	5592-5602	procedures	_
27-37	5603-5605	or	_
27-38	5606-5611	exact	_
27-39	5612-5618	tissue	_
27-40	5619-5630	composition	_
27-41	5631-5632	,	_
27-42	5633-5636	all	_
27-43	5637-5639	of	_
27-44	5640-5645	which	_
27-45	5646-5650	have	_
27-46	5651-5653	to	_
27-47	5654-5656	be	_
27-48	5657-5668	interpreted	_
27-49	5669-5671	at	_
27-50	5672-5675	the	_
27-51	5676-5686	discretion	_
27-52	5687-5689	of	_
27-53	5690-5693	the	_
27-54	5694-5703	scientist	_
27-55	5704-5705	.	_

28-1	5706-5714	Neuronal	_
28-2	5715-5736	Differentiation/Short	_
28-3	5737-5740	RNA	_
28-4	5741-5751	Sequencing	_
28-5	5752-5757	Model	_
28-6	5758-5764	LA-N-2	_
28-7	5765-5768	and	_
28-8	5769-5775	LA-N-5	_
28-9	5776-5781	cells	_
28-10	5782-5789	respond	_
28-11	5790-5792	to	_
28-12	5793-5800	ciliary	_
28-13	5801-5813	neurotrophic	_
28-14	5814-5820	factor	_
28-15	5821-5822	(	_
28-16	5823-5827	CNTF	_
28-17	5828-5829	)	_
28-18	5830-5832	by	_
28-19	5833-5844	cholinergic	_
28-20	5845-5860	differentiation	_
28-21	5861-5874	corresponding	_
28-22	5875-5879	with	_
28-23	5880-5889	elevation	_
28-24	5890-5892	of	_
28-25	5893-5900	choline	_
28-26	5901-5918	acetyltransferase	_
28-27	5919-5920	(	_
28-28	5921-5925	ChAT	_
28-29	5926-5927	)	_
28-30	5928-5929	,	_
28-31	5930-5933	the	_
28-32	5934-5941	central	_
28-33	5942-5953	cholinergic	_
28-34	5954-5960	marker	_
28-35	5961-5962	(	_
28-36	5963-5967	mRNA	_
28-37	5968-5969	,	_
28-38	5970-5977	protein	_
28-39	5978-5979	,	_
28-40	5980-5983	and	_
28-41	5984-5992	activity	_
28-42	5993-5994	)	_
28-43	5995-5997	as	_
28-44	5998-6002	well	_
28-45	6003-6005	as	_
28-46	6006-6009	its	_
28-47	6010-6018	intronic	_
28-48	6019-6028	vesicular	_
28-49	6029-6044	ACh-transporter	_
28-50	6045-6049	gene	_
28-51	6050-6051	,	_
28-52	6052-6057	vAChT	_
28-53	6058-6059	(	_
28-54	6060-6063	aka	_
28-55	6064-6071	SLC18A3	_
28-56	6072-6073	)	_
28-57	6074-6075	.	_

29-1	6076-6078	We	_
29-2	6079-6087	measured	_
29-3	6088-6091	the	_
29-4	6092-6099	changes	_
29-5	6100-6102	in	_
29-6	6103-6108	short	_
29-7	6109-6112	RNA	_
29-8	6113-6119	levels	_
29-9	6120-6129	following	_
29-10	6130-6134	this	_
29-11	6135-6147	intervention	_
29-12	6148-6150	at	_
29-13	6151-6158	several	_
29-14	6159-6163	time	_
29-15	6164-6170	points	_
29-16	6171-6172	.	_

30-1	6173-6188	Differentiation	_
30-2	6189-6191	To	_
30-3	6192-6201	determine	_
30-4	6202-6211	effective	_
30-5	6212-6226	concentrations	_
30-6	6227-6229	of	_
30-7	6230-6233	the	_
30-8	6234-6249	differentiation	_
30-9	6250-6255	agent	_
30-10	6256-6257	,	_
30-11	6258-6260	we	_
30-12	6261-6270	performed	_
30-13	6271-6272	a	_
30-14	6273-6286	dose-response	_
30-15	6287-6297	experiment	_
30-16	6298-6302	with	_
30-17	6303-6307	both	_
30-18	6308-6312	cell	_
30-19	6313-6318	lines	_
30-20	6319-6320	.	_

31-1	6321-6326	Cells	_
31-2	6327-6331	were	_
31-3	6332-6338	seeded	_
31-4	6339-6341	at	_
31-5	6342-6355	approximately	_
31-6	6356-6359	200	_
31-7	6360-6363	000	_
31-8	6364-6369	cells	_
31-9	6370-6373	per	_
31-10	6374-6378	well	_
31-11	6379-6381	in	_
31-12	6382-6389	12-well	_
31-13	6390-6396	plates	_
31-14	6397-6398	,	_
31-15	6399-6402	and	_
31-16	6403-6408	after	_
31-17	6409-6412	24h	_
31-18	6413-6422	incubated	_
31-19	6423-6427	with	_
31-20	6428-6429	1	_
31-21	6430-6431	,	_
31-22	6432-6434	10	_
31-23	6435-6436	,	_
31-24	6437-6439	or	_
31-25	6440-6443	100	_
31-26	6444-6449	ng/ml	_
31-27	6450-6454	CNTF	_
31-28	6455-6456	(	_
31-29	6457-6470	Sigma-Aldrich	_
31-30	6471-6472	)	_
31-31	6473-6474	.	_

32-1	6475-6488	Dose-response	_
32-2	6489-6492	was	_
32-3	6493-6501	measured	_
32-4	6502-6504	by	_
32-5	6505-6509	qPCR	_
32-6	6510-6512	of	_
32-7	6513-6517	CHAT	_
32-8	6518-6522	mRNA	_
32-9	6523-6524	,	_
32-10	6525-6527	at	_
32-11	6528-6532	time	_
32-12	6533-6539	points	_
32-13	6540-6542	30	_
32-14	6543-6550	minutes	_
32-15	6551-6552	,	_
32-16	6553-6555	60	_
32-17	6556-6563	minutes	_
32-18	6564-6565	,	_
32-19	6566-6567	2	_
32-20	6568-6572	days	_
32-21	6573-6574	,	_
32-22	6575-6578	and	_
32-23	6579-6580	4	_
32-24	6581-6585	days	_
32-25	6586-6587	.	_

33-1	6588-6591	For	_
33-2	6592-6596	each	_
33-3	6597-6603	sample	_
33-4	6604-6605	,	_
33-5	6606-6607	a	_
33-6	6608-6621	corresponding	_
33-7	6622-6629	control	_
33-8	6630-6637	culture	_
33-9	6638-6641	was	_
33-10	6642-6651	generated	_
33-11	6652-6653	.	_

34-1	6654-6657	RNA	_
34-2	6658-6668	Extraction	_
34-3	6669-6672	for	_
34-4	6673-6677	qPCR	_
34-5	6678-6681	and	_
34-6	6682-6692	Sequencing	_
34-7	6693-6696	RNA	_
34-8	6697-6700	was	_
34-9	6701-6710	extracted	_
34-10	6711-6713	in	_
34-11	6714-6724	biological	_
34-12	6725-6739	quadruplicates	_
34-13	6740-6745	using	_
34-14	6746-6752	TRIzol	_
34-15	6753-6762	according	_
34-16	6763-6765	to	_
34-17	6766-6769	the	_
34-18	6770-6784	manufacturer′s	_
34-19	6785-6797	instructions	_
34-20	6798-6799	,	_
34-21	6800-6802	as	_
34-22	6803-6812	described	_
34-23	6813-6815	in	_
34-24	6816-6817	.	_

35-1	6818-6821	RNA	_
35-2	6822-6825	was	_
35-3	6826-6838	precipitated	_
35-4	6839-6844	using	_
35-5	6845-6852	ethanol	_
35-6	6853-6854	,	_
35-7	6855-6861	washed	_
35-8	6862-6863	,	_
35-9	6864-6867	and	_
35-10	6868-6877	air-dried	_
35-11	6878-6884	before	_
35-12	6885-6897	resuspension	_
35-13	6898-6900	in	_
35-14	6901-6911	RNase-free	_
35-15	6912-6917	water	_
35-16	6918-6919	.	_

36-1	6920-6933	Concentration	_
36-2	6934-6937	was	_
36-3	6938-6946	measured	_
36-4	6947-6949	by	_
36-5	6950-6958	Nanodrop	_
36-6	6959-6963	2000	_
36-7	6964-6965	(	_
36-8	6966-6978	ThermoFisher	_
36-9	6979-6989	Scientific	_
36-10	6990-6991	)	_
36-11	6992-6993	,	_
36-12	6994-6997	RNA	_
36-13	6998-7005	quality	_
36-14	7006-7009	was	_
36-15	7010-7018	measured	_
36-16	7019-7022	via	_
36-17	7023-7034	Bioanalyzer	_
36-18	7035-7039	2100	_
36-19	7040-7041	(	_
36-20	7042-7049	Agilent	_
36-21	7050-7051	)	_
36-22	7052-7053	.	_

37-1	7054-7057	RNA	_
37-2	7058-7065	quality	_
37-3	7066-7069	for	_
37-4	7070-7073	all	_
37-5	7074-7081	samples	_
37-6	7082-7085	was	_
37-7	7086-7090	near	_
37-8	7091-7098	optimal	_
37-9	7099-7100	(	_
37-10	7101-7104	RIN	_
37-11	7105-7106	>	_
37-12	7107-7108	9	_
37-13	7109-7110	)	_
37-14	7111-7112	.	_

38-1	7113-7125	Quantitative	_
38-2	7126-7135	Real-time	_
38-3	7136-7139	PCR	_
38-4	7140-7143	RNA	_
38-5	7144-7147	was	_
38-6	7148-7156	analyzed	_
38-7	7157-7159	on	_
38-8	7160-7161	a	_
38-9	7162-7168	BioRad	_
38-10	7169-7174	CFX96	_
38-11	7175-7184	real-time	_
38-12	7185-7188	PCR	_
38-13	7189-7195	cycler	_
38-14	7196-7201	using	_
38-15	7202-7209	PowerUp	_
38-16	7210-7214	SYBR	_
38-17	7215-7220	Green	_
38-18	7221-7227	Master	_
38-19	7228-7231	Mix	_
38-20	7232-7233	(	_
38-21	7234-7241	Applied	_
38-22	7242-7252	Biosystems	_
38-23	7253-7254	)	_
38-24	7255-7257	in	_
38-25	7258-7267	technical	_
38-26	7268-7278	duplicates	_
38-27	7279-7280	.	_

39-1	7281-7288	Primers	_
39-2	7289-7293	were	_
39-3	7294-7302	designed	_
39-4	7303-7308	using	_
39-5	7309-7316	primer3	_
39-6	7317-7320	and	_
39-7	7321-7324	are	_
39-8	7325-7327	as	_
39-9	7328-7335	follows	_
39-10	7336-7337	(	_
39-11	7338-7340	5′	_
39-12	7341-7343	to	_
39-13	7344-7346	3′	_
39-14	7347-7348	)	_
39-15	7349-7350	:	_
39-16	7351-7355	ChAT	_
39-17	7356-7357	[	_
39-18	7358-7360	FW	_
39-19	7361-7362	:	_
39-20	7363-7366	CAC	_
39-21	7367-7370	TTG	_
39-22	7371-7374	GTG	_
39-23	7375-7378	TCT	_
39-24	7379-7382	GAG	_
39-25	7383-7385	CA	_
39-26	7386-7387	,	_
39-27	7388-7390	RV	_
39-28	7391-7392	:	_
39-29	7393-7396	AGT	_
39-30	7397-7400	TTC	_
39-31	7401-7404	TGC	_
39-32	7405-7408	TGC	_
39-33	7409-7412	AGG	_
39-34	7413-7416	GTC	_
39-35	7417-7419	TC	_
39-36	7420-7421	]	_
39-37	7422-7423	,	_
39-38	7424-7428	ACTB	_
39-39	7429-7430	(	_
39-40	7431-7443	housekeeping	_
39-41	7444-7445	)	_
39-42	7446-7447	[	_
39-43	7448-7450	FW	_
39-44	7451-7452	:	_
39-45	7453-7456	GCT	_
39-46	7457-7460	GTA	_
39-47	7461-7464	TTC	_
39-48	7465-7468	CCC	_
39-49	7469-7472	TCC	_
39-50	7473-7476	ATC	_
39-51	7477-7479	GT	_
39-52	7480-7481	,	_
39-53	7482-7484	RV	_
39-54	7485-7486	:	_
39-55	7487-7490	CTT	_
39-56	7491-7494	CTC	_
39-57	7495-7498	CAT	_
39-58	7499-7502	GTC	_
39-59	7503-7506	GTC	_
39-60	7507-7510	CCA	_
39-61	7511-7513	GT	_
39-62	7514-7515	]	_
39-63	7516-7517	;	_
39-64	7518-7528	additional	_
39-65	7529-7536	primers	_
39-66	7537-7541	were	_
39-67	7542-7549	ordered	_
39-68	7550-7554	from	_
39-69	7555-7561	BioRad	_
39-70	7562-7563	,	_
39-71	7564-7571	Germany	_
39-72	7572-7573	:	_
39-73	7574-7579	vAChT	_
39-74	7580-7581	[	_
39-75	7582-7590	PrimePCR	_
39-76	7591-7592	“	_
39-77	7593-7607	qHsaCED0047922	_
39-78	7608-7609	”	_
39-79	7610-7611	]	_
39-80	7612-7613	,	_
39-81	7614-7619	RPLP0	_
39-82	7620-7621	(	_
39-83	7622-7634	housekeeping	_
39-84	7635-7636	)	_
39-85	7637-7638	[	_
39-86	7639-7647	PrimePCR	_
39-87	7648-7649	“	_
39-88	7650-7664	qHsaCED0038653	_
39-89	7665-7666	”	_
39-90	7667-7668	]	_
39-91	7669-7670	.	_

40-1	7671-7675	Data	_
40-2	7676-7680	were	_
40-3	7681-7689	analyzed	_
40-4	7690-7694	with	_
40-5	7695-7701	BioRad	_
40-6	7702-7705	CFX	_
40-7	7706-7713	manager	_
40-8	7714-7717	and	_
40-9	7718-7728	expression	_
40-10	7729-7735	values	_
40-11	7736-7737	(	_
40-12	7738-7748	normalized	_
40-13	7749-7751	to	_
40-14	7752-7764	housekeeping	_
40-15	7765-7770	genes	_
40-16	7771-7772	)	_
40-17	7773-7781	exported	_
40-18	7782-7785	for	_
40-19	7786-7797	statistical	_
40-20	7798-7805	testing	_
40-21	7806-7808	in	_
40-22	7809-7811	R.	_
40-23	7812-7817	Short	_
40-24	7818-7821	RNA	_
40-25	7822-7832	Sequencing	_
40-26	7833-7838	Short	_
40-27	7839-7842	RNA	_
40-28	7843-7853	sequencing	_
40-29	7854-7857	was	_
40-30	7858-7867	performed	_
40-31	7868-7873	using	_
40-32	7874-7882	Illumina	_
40-33	7883-7890	NextSeq	_
40-34	7891-7894	550	_
40-35	7895-7904	according	_
40-36	7905-7907	to	_
40-37	7908-7911	the	_
40-38	7912-7924	manufacturer	_
40-39	7925-7926	’	_
40-40	7927-7928	s	_
40-41	7929-7941	instructions	_
40-42	7942-7943	,	_
40-43	7944-7949	after	_
40-44	7950-7954	cDNA	_
40-45	7955-7962	library	_
40-46	7963-7974	preparation	_
40-47	7975-7980	using	_
40-48	7981-7984	the	_
40-49	7985-7992	NEBNext	_
40-50	7993-8002	Multiplex	_
40-51	8003-8008	Small	_
40-52	8009-8012	RNA	_
40-53	8013-8020	Library	_
40-54	8021-8025	Prep	_
40-55	8026-8029	Set	_
40-56	8030-8033	for	_
40-57	8034-8042	Illumina	_
40-58	8043-8044	(	_
40-59	8045-8048	New	_
40-60	8049-8056	England	_
40-61	8057-8064	BioLabs	_
40-62	8065-8066	)	_
40-63	8067-8069	as	_
40-64	8070-8079	described	_
40-65	8080-8081	.	_

41-1	8082-8091	Sequenced	_
41-2	8092-8097	reads	_
41-3	8098-8102	were	_
41-4	8103-8110	aligned	_
41-5	8111-8113	to	_
41-6	8114-8121	miRBase	_
41-7	8122-8125	v21	_
41-8	8126-8135	sequences	_
41-9	8136-8139	via	_
41-10	8140-8150	miRExpress	_
41-11	8151-8152	(	_
41-12	8153-8160	version	_
41-13	8161-8166	2.1.4	_
41-14	8167-8168	)	_
41-15	8169-8170	.	_

42-1	8171-8183	Differential	_
42-2	8184-8194	expression	_
42-3	8195-8198	was	_
42-4	8199-8209	determined	_
42-5	8210-8213	via	_
42-6	8214-8222	R/DESeq2	_
42-7	8223-8224	.	_

43-1	8225-8228	The	_
43-2	8229-8241	Count-Change	_
43-3	8242-8248	Metric	_
43-4	8249-8251	We	_
43-5	8252-8262	calculated	_
43-6	8263-8266	the	_
43-7	8267-8279	count-change	_
43-8	8280-8283	for	_
43-9	8284-8294	individual	_
43-10	8295-8299	miRs	_
43-11	8300-8302	by	_
43-12	8303-8312	combining	_
43-13	8313-8317	base	_
43-14	8318-8322	mean	_
43-15	8323-8333	expression	_
43-16	8334-8338	with	_
43-17	8339-8342	the	_
43-18	8343-8359	de-logarithmized	_
43-19	8360-8371	fold-change	_
43-20	8372-8373	(	_
43-21	8374-8378	from	_
43-22	8379-8385	DESeq2	_
43-23	8386-8392	output	_
43-24	8393-8394	)	_
43-25	8395-8398	.CC	_
43-26	8399-8400	:	_
43-27	8401-8412	countChange	_
43-28	8413-8414	,	_
43-29	8415-8417	BM	_
43-30	8418-8419	:	_
43-31	8420-8428	baseMean	_
43-32	8429-8430	,	_
43-33	8431-8434	LFC	_
43-34	8435-8436	:	_
43-35	8437-8446	log2-fold	_
43-36	8447-8453	change	_
43-37	8454-8456	It	_
43-38	8457-8459	is	_
43-39	8460-8469	important	_
43-40	8470-8472	to	_
43-41	8473-8477	note	_
43-42	8478-8482	that	_
43-43	8483-8486	the	_
43-44	8487-8499	count-change	_
43-45	8500-8506	metric	_
43-46	8507-8508	,	_
43-47	8509-8511	by	_
43-48	8512-8520	deriving	_
43-49	8521-8525	from	_
43-50	8526-8529	the	_
43-51	8530-8534	base	_
43-52	8535-8539	mean	_
43-53	8540-8550	expression	_
43-54	8551-8557	across	_
43-55	8558-8565	samples	_
43-56	8566-8567	,	_
43-57	8568-8570	is	_
43-58	8571-8580	dependent	_
43-59	8581-8583	on	_
43-60	8584-8594	sequencing	_
43-61	8595-8600	depth	_
43-62	8601-8602	,	_
43-63	8603-8606	and	_
43-64	8607-8611	thus	_
43-65	8612-8614	is	_
43-66	8615-8618	not	_
43-67	8619-8628	instantly	_
43-68	8629-8642	generalizable	_
43-69	8643-8644	,	_
43-70	8645-8648	for	_
43-71	8649-8657	instance	_
43-72	8658-8662	when	_
43-73	8663-8672	comparing	_
43-74	8673-8682	different	_
43-75	8683-8694	experiments	_
43-76	8695-8696	.	_

44-1	8697-8704	However	_
44-2	8705-8706	,	_
44-3	8707-8709	it	_
44-4	8710-8715	could	_
44-5	8716-8718	be	_
44-6	8719-8729	normalized	_
44-7	8730-8732	to	_
44-8	8733-8734	a	_
44-9	8735-8741	degree	_
44-10	8742-8744	by	_
44-11	8745-8756	considering	_
44-12	8757-8760	the	_
44-13	8761-8766	total	_
44-14	8767-8773	amount	_
44-15	8774-8776	of	_
44-16	8777-8780	raw	_
44-17	8781-8786	reads	_
44-18	8787-8796	generated	_
44-19	8797-8801	from	_
44-20	8802-8806	each	_
44-21	8807-8813	sample	_
44-22	8814-8815	.	_

45-1	8816-8835	Whole-Transcriptome	_
45-2	8836-8849	Meta-analysis	_
45-3	8850-8854	Data	_
45-4	8855-8866	Preparation	_
45-5	8867-8869	We	_
45-6	8870-8879	processed	_
45-7	8880-8893	web-available	_
45-8	8894-8901	patient	_
45-9	8902-8915	transcriptome	_
45-10	8916-8924	datasets	_
45-11	8925-8927	by	_
45-12	8928-8944	state-of-the-art	_
45-13	8945-8955	procedures	_
45-14	8956-8957	,	_
45-15	8958-8967	analogous	_
45-16	8968-8970	to	_
45-17	8971-8972	,	_
45-18	8973-8975	to	_
45-19	8976-8984	generate	_
45-20	8985-9000	transcriptional	_
45-21	9001-9008	disease	_
45-22	9009-9017	profiles	_
45-23	9018-9019	.	_

46-1	9020-9023	The	_
46-2	9024-9033	following	_
46-3	9034-9035	R	_
46-4	9036-9044	packages	_
46-5	9045-9046	(	_
46-6	9047-9059	Bioconductor	_
46-7	9060-9061	)	_
46-8	9062-9066	were	_
46-9	9067-9071	used	_
46-10	9072-9081	according	_
46-11	9082-9084	to	_
46-12	9085-9088	the	_
46-13	9089-9098	developer	_
46-14	9099-9100	’	_
46-15	9101-9102	s	_
46-16	9103-9115	instructions	_
46-17	9116-9117	:	_
46-18	9118-9121	Raw	_
46-19	9122-9126	data	_
46-20	9127-9131	read	_
46-21	9132-9133	,	_
46-22	9134-9137	RMA	_
46-23	9138-9151	normalization	_
46-24	9152-9153	,	_
46-25	9154-9157	RNA	_
46-26	9158-9169	degradation	_
46-27	9170-9171	:	_
46-28	9172-9176	affy	_
46-29	9177-9178	.	_

47-1	9179-9184	Batch	_
47-2	9185-9195	correction	_
47-3	9196-9197	(	_
47-4	9198-9200	as	_
47-5	9201-9204	per	_
47-6	9205-9209	chip	_
47-7	9210-9214	scan	_
47-8	9215-9219	date	_
47-9	9220-9221	)	_
47-10	9222-9230	involved	_
47-11	9231-9232	:	_
47-12	9233-9236	sva	_
47-13	9237-9238	(	_
47-14	9239-9245	Combat	_
47-15	9246-9247	)	_
47-16	9248-9249	.	_

48-1	9250-9258	Outliers	_
48-2	9259-9263	were	_
48-3	9264-9271	removed	_
48-4	9272-9274	as	_
48-5	9275-9284	described	_
48-6	9285-9287	in	_
48-7	9288-9289	.	_

49-1	9290-9293	The	_
49-2	9294-9299	array	_
49-3	9300-9306	probes	_
49-4	9307-9311	were	_
49-5	9312-9321	annotated	_
49-6	9322-9325	via	_
49-7	9326-9333	ENSEMBL	_
49-8	9334-9338	gene	_
49-9	9339-9341	ID	_
49-10	9342-9343	,	_
49-11	9344-9352	database	_
49-12	9353-9360	version	_
49-13	9361-9364	v75	_
49-14	9365-9366	,	_
49-15	9367-9369	to	_
49-16	9370-9376	ensure	_
49-17	9377-9387	congruency	_
49-18	9388-9392	with	_
49-19	9393-9398	prior	_
49-20	9399-9407	analyses	_
49-21	9408-9409	,	_
49-22	9410-9415	using	_
49-23	9416-9423	biomaRt	_
49-24	9424-9425	,	_
49-25	9426-9429	and	_
49-26	9430-9434	were	_
49-27	9435-9444	collapsed	_
49-28	9445-9448	via	_
49-29	9449-9452	the	_
49-30	9453-9465	collapseRows	_
49-31	9466-9474	function	_
49-32	9475-9477	of	_
49-33	9478-9483	WGCNA	_
49-34	9484-9485	.	_

50-1	9486-9491	Prior	_
50-2	9492-9494	to	_
50-3	9495-9506	application	_
50-4	9507-9509	of	_
50-5	9510-9513	the	_
50-6	9514-9525	generalized	_
50-7	9526-9532	linear	_
50-8	9533-9538	mixed	_
50-9	9539-9544	model	_
50-10	9545-9546	(	_
50-11	9547-9551	nlme	_
50-12	9552-9553	)	_
50-13	9554-9555	,	_
50-14	9556-9564	datasets	_
50-15	9565-9569	were	_
50-16	9570-9580	rebalanced	_
50-17	9581-9584	and	_
50-18	9585-9594	regressed	_
50-19	9595-9597	to	_
50-20	9598-9605	correct	_
50-21	9606-9609	for	_
50-22	9610-9619	technical	_
50-23	9620-9623	and	_
50-24	9624-9634	biological	_
50-25	9635-9644	covariate	_
50-26	9645-9655	influences	_
50-27	9656-9657	.	_

51-1	9658-9668	Regression	_
51-2	9669-9677	Analysis	_
51-3	9678-9691	Meta-analysis	_
51-4	9692-9694	on	_
51-5	9695-9698	all	_
51-6	9699-9704	genes	_
51-7	9705-9712	present	_
51-8	9713-9715	in	_
51-9	9716-9719	all	_
51-10	9720-9728	datasets	_
51-11	9729-9730	(	_
51-12	9731-9737	12,391	_
51-13	9738-9743	genes	_
51-14	9744-9746	in	_
51-15	9747-9752	total	_
51-16	9753-9754	)	_
51-17	9755-9763	employed	_
51-18	9764-9765	a	_
51-19	9766-9777	generalized	_
51-20	9778-9784	linear	_
51-21	9785-9790	mixed	_
51-22	9791-9796	model	_
51-23	9797-9799	to	_
51-24	9800-9807	account	_
51-25	9808-9811	for	_
51-26	9812-9821	variation	_
51-27	9822-9825	per	_
51-28	9826-9833	dataset	_
51-29	9834-9837	and	_
51-30	9838-9848	individual	_
51-31	9849-9850	,	_
51-32	9851-9859	yielding	_
51-33	9860-9869	log2-fold	_
51-34	9870-9876	change	_
51-35	9877-9878	(	_
51-36	9879-9884	logFC	_
51-37	9885-9886	)	_
51-38	9887-9893	values	_
51-39	9894-9897	for	_
51-40	9898-9902	each	_
51-41	9903-9907	gene	_
51-42	9908-9915	between	_
51-43	9916-9923	control	_
51-44	9924-9927	and	_
51-45	9928-9935	disease	_
51-46	9936-9937	,	_
51-47	9938-9943	which	_
51-48	9944-9948	were	_
51-49	9949-9959	correlated	_
51-50	9960-9967	between	_
51-51	9968-9971	SCZ	_
51-52	9972-9975	and	_
51-53	9976-9978	BD	_
51-54	9979-9984	using	_
51-55	9985-9993	Spearman	_
51-56	9994-9995	’	_
51-57	9996-9997	s	_
51-58	9998-10004	method	_
51-59	10005-10006	.	_

52-1	10007-10009	To	_
52-2	10010-10019	determine	_
52-3	10020-10032	significance	_
52-4	10033-10034	,	_
52-5	10035-10038	the	_
52-6	10039-10052	meta-analysis	_
52-7	10053-10060	process	_
52-8	10061-10064	was	_
52-9	10065-10073	repeated	_
52-10	10074-10080	10,000	_
52-11	10081-10086	times	_
52-12	10087-10091	with	_
52-13	10092-10102	randomized	_
52-14	10103-10115	case/control	_
52-15	10116-10122	status	_
52-16	10123-10124	,	_
52-17	10125-10132	forming	_
52-18	10133-10134	a	_
52-19	10135-10146	permutation	_
52-20	10147-10151	null	_
52-21	10152-10164	distribution	_
52-22	10165-10167	of	_
52-23	10168-10171	the	_
52-24	10172-10182	individual	_
52-25	10183-10194	correlation	_
52-26	10195-10207	coefficients	_
52-27	10208-10209	(	_
52-28	10210-10216	Figure	_
52-29	10217-10219	S3	_
52-30	10220-10221	)	_
52-31	10222-10223	.	_

53-1	10224-10226	Of	_
53-2	10227-10231	note	_
53-3	10232-10233	,	_
53-4	10234-10241	several	_
53-5	10242-10253	cholinergic	_
53-6	10254-10257	and	_
53-7	10258-10267	neurokine	_
53-8	10268-10273	genes	_
53-9	10274-10278	were	_
53-10	10279-10286	missing	_
53-11	10287-10291	from	_
53-12	10292-10295	the	_
53-13	10296-10308	whole-genome	_
53-14	10309-10322	meta-analysis	_
53-15	10323-10330	because	_
53-16	10331-10333	of	_
53-17	10334-10344	annotation	_
53-18	10345-10353	deficits	_
53-19	10354-10355	(	_
53-20	10356-10362	CHRNA7	_
53-21	10363-10364	,	_
53-22	10365-10370	CHRM1	_
53-23	10371-10372	,	_
53-24	10373-10377	LHX8	_
53-25	10378-10379	,	_
53-26	10380-10384	CHKB	_
53-27	10385-10386	,	_
53-28	10387-10393	PRIMA1	_
53-29	10394-10395	,	_
53-30	10396-10400	CNTF	_
53-31	10401-10402	)	_
53-32	10403-10404	,	_
53-33	10405-10408	and	_
53-34	10409-10410	,	_
53-35	10411-10413	at	_
53-36	10414-10418	this	_
53-37	10419-10424	stage	_
53-38	10425-10426	,	_
53-39	10427-10432	could	_
53-40	10433-10436	not	_
53-41	10437-10439	be	_
53-42	10440-10446	easily	_
53-43	10447-10460	re-introduced	_
53-44	10461-10462	.	_

54-1	10463-10467	Gene	_
54-2	10468-10476	Ontology	_
54-3	10477-10478	(	_
54-4	10479-10481	GO	_
54-5	10482-10483	)	_
54-6	10484-10494	Enrichment	_
54-7	10495-10503	Analyses	_
54-8	10504-10506	To	_
54-9	10507-10512	focus	_
54-10	10513-10515	on	_
54-11	10516-10519	the	_
54-12	10520-10531	differences	_
54-13	10532-10533	,	_
54-14	10534-10536	as	_
54-15	10537-10544	opposed	_
54-16	10545-10547	to	_
54-17	10548-10551	the	_
54-18	10552-10564	similarities	_
54-19	10565-10566	,	_
54-20	10567-10574	between	_
54-21	10575-10577	BD	_
54-22	10578-10581	and	_
54-23	10582-10585	SCZ	_
54-24	10586-10593	patient	_
54-25	10594-10599	brain	_
54-26	10600-10614	transcriptomes	_
54-27	10615-10616	,	_
54-28	10617-10619	we	_
54-29	10620-10629	performed	_
54-30	10630-10632	GO	_
54-31	10633-10643	enrichment	_
54-32	10644-10652	analysis	_
54-33	10653-10655	on	_
54-34	10656-10659	the	_
54-35	10660-10665	genes	_
54-36	10666-10673	showing	_
54-37	10674-10677	the	_
54-38	10678-10685	highest	_
54-39	10686-10690	rank	_
54-40	10691-10702	differences	_
54-41	10703-10710	between	_
54-42	10711-10719	datasets	_
54-43	10720-10721	(	_
54-44	10722-10728	Figure	_
54-45	10729-10731	S4	_
54-46	10732-10733	)	_
54-47	10734-10735	,	_
54-48	10736-10741	using	_
54-49	10742-10745	the	_
54-50	10746-10747	R	_
54-51	10748-10755	package	_
54-52	10756-10761	topGO	_
54-53	10762-10763	.	_

55-1	10764-10771	Briefly	_
55-2	10772-10773	,	_
55-3	10774-10776	we	_
55-4	10777-10786	evaluated	_
55-5	10787-10788	(	_
55-6	10789-10796	smaller	_
55-7	10797-10798	)	_
55-8	10799-10805	groups	_
55-9	10806-10808	of	_
55-10	10809-10814	genes	_
55-11	10815-10818	for	_
55-12	10819-10829	enrichment	_
55-13	10830-10837	against	_
55-14	10838-10839	a	_
55-15	10840-10841	(	_
55-16	10842-10848	bigger	_
55-17	10849-10850	)	_
55-18	10851-10861	background	_
55-19	10862-10864	of	_
55-20	10865-10870	genes	_
55-21	10871-10874	for	_
55-22	10875-10883	presence	_
55-23	10884-10886	in	_
55-24	10887-10897	individual	_
55-25	10898-10900	GO	_
55-26	10901-10906	terms	_
55-27	10907-10916	exceeding	_
55-28	10917-10928	statistical	_
55-29	10929-10938	estimates	_
55-30	10939-10940	.	_

56-1	10941-10944	The	_
56-2	10945-10955	background	_
56-3	10956-10965	comprised	_
56-4	10966-10968	of	_
56-5	10969-10972	the	_
56-6	10973-10978	first	_
56-7	10979-10983	2000	_
56-8	10984-10989	genes	_
56-9	10990-10999	according	_
56-10	11000-11002	to	_
56-11	11003-11006	the	_
56-12	11007-11014	applied	_
56-13	11015-11019	rank	_
56-14	11020-11026	system	_
56-15	11027-11028	,	_
56-16	11029-11037	computed	_
56-17	11038-11040	as	_
56-18	11041-11042	a	_
56-19	11043-11051	function	_
56-20	11052-11054	of	_
56-21	11055-11063	Spearman	_
56-22	11064-11065	’	_
56-23	11066-11067	s	_
56-24	11068-11072	rank	_
56-25	11073-11084	differences	_
56-26	11085-11087	of	_
56-27	11088-11098	regression	_
56-28	11099-11103	beta	_
56-29	11104-11110	values	_
56-30	11111-11112	(	_
56-31	11113-11118	logFC	_
56-32	11119-11120	)	_
56-33	11121-11128	between	_
56-34	11129-11132	the	_
56-35	11133-11136	two	_
56-36	11137-11145	compared	_
56-37	11146-11152	groups	_
56-38	11153-11154	,	_
56-39	11155-11161	either	_
56-40	11162-11164	as	_
56-41	11165-11173	absolute	_
56-42	11174-11180	values	_
56-43	11181-11183	or	_
56-44	11184-11185	“	_
56-45	11186-11188	as	_
56-46	11189-11191	is	_
56-47	11192-11193	”	_
56-48	11194-11195	(	_
56-49	11196-11205	elevation	_
56-50	11206-11208	in	_
56-51	11209-11212	one	_
56-52	11213-11218	group	_
56-53	11219-11221	as	_
56-54	11222-11229	opposed	_
56-55	11230-11232	to	_
56-56	11233-11236	the	_
56-57	11237-11242	other	_
56-58	11243-11244	)	_
56-59	11245-11246	.	_

57-1	11247-11250	The	_
57-2	11251-11257	target	_
57-3	11258-11263	genes	_
57-4	11264-11266	of	_
57-5	11267-11270	the	_
57-6	11271-11279	analysis	_
57-7	11280-11284	were	_
57-8	11285-11292	defined	_
57-9	11293-11295	as	_
57-10	11296-11299	the	_
57-11	11300-11303	100	_
57-12	11304-11307	top	_
57-13	11308-11314	ranked	_
57-14	11315-11320	genes	_
57-15	11321-11322	(	_
57-16	11323-11326	top	_
57-17	11327-11328	5	_
57-18	11329-11330	%	_
57-19	11331-11333	of	_
57-20	11334-11344	background	_
57-21	11345-11346	)	_
57-22	11347-11348	,	_
57-23	11349-11355	unless	_
57-24	11356-11365	otherwise	_
57-25	11366-11372	stated	_
57-26	11373-11374	.	_

58-1	11375-11388	Statistically	_
58-2	11389-11400	significant	_
58-3	11401-11403	GO	_
58-4	11404-11411	results	_
58-5	11412-11416	were	_
58-6	11417-11425	compiled	_
58-7	11426-11429	and	_
58-8	11430-11437	curated	_
58-9	11438-11441	for	_
58-10	11442-11454	CNS-relevant	_
58-11	11455-11460	terms	_
58-12	11461-11462	.	_

59-1	11463-11466	Sex	_
59-2	11467-11476	Influence	_
59-3	11477-11479	on	_
59-4	11480-11494	Transcriptomic	_
59-5	11495-11506	Differences	_
59-6	11507-11515	Studying	_
59-7	11516-11529	web-available	_
59-8	11530-11538	datasets	_
59-9	11539-11541	of	_
59-10	11542-11558	non-degenerative	_
59-11	11559-11565	mental	_
59-12	11566-11573	disease	_
59-13	11574-11582	patients	_
59-14	11583-11591	revealed	_
59-15	11592-11596	that	_
59-16	11597-11600	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
59-17	11601-11604	and	_
59-18	11605-11607	BD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
59-19	11608-11616	datasets	_
59-20	11617-11626	possessed	_
59-21	11627-11637	sufficient	_
59-22	11638-11645	numbers	_
59-23	11646-11648	to	_
59-24	11649-11654	allow	_
59-25	11655-11673	sex-discriminative	_
59-26	11674-11687	meta-analysis	_
59-27	11688-11690	of	_
59-28	11691-11702	statistical	_
59-29	11703-11715	significance	_
59-30	11716-11717	.	_

60-1	11718-11723	Hence	_
60-2	11724-11725	,	_
60-3	11726-11728	we	_
60-4	11729-11737	repeated	_
60-5	11738-11741	the	_
60-6	11742-11747	above	_
60-7	11748-11753	steps	_
60-8	11754-11757	for	_
60-9	11758-11761	the	_
60-10	11762-11772	individual	_
60-11	11773-11780	subsets	_
60-12	11781-11783	of	_
60-13	11784-11788	male	_
60-14	11789-11792	and	_
60-15	11793-11799	female	_
60-16	11800-11808	patients	_
60-17	11809-11810	,	_
60-18	11811-11815	with	_
60-19	11816-11819	the	_
60-20	11820-11824	sole	_
60-21	11825-11831	change	_
60-22	11832-11834	of	_
60-23	11835-11846	eliminating	_
60-24	11847-11850	the	_
60-25	11851-11860	covariate	_
60-26	11861-11871	regression	_
60-27	11872-11875	for	_
60-28	11876-11879	sex	_
60-29	11880-11881	,	_
60-30	11882-11884	as	_
60-31	11885-11889	this	_
60-32	11890-11895	would	_
60-33	11896-11904	preclude	_
60-34	11905-11912	further	_
60-35	11913-11921	analysis	_
60-36	11922-11924	of	_
60-37	11925-11929	this	_
60-38	11930-11938	variable	_
60-39	11939-11940	,	_
60-40	11941-11943	in	_
60-41	11944-11945	4	_
60-42	11946-11954	distinct	_
60-43	11955-11957	GO	_
60-44	11958-11968	enrichment	_
60-45	11969-11974	group	_
60-46	11975-11986	comparisons	_
60-47	11987-11994	between	_
60-48	11995-12005	SCZ-biased	_
60-49	12006-12007	,	_
60-50	12008-12017	BD-biased	_
60-51	12018-12019	,	_
60-52	12020-12031	male-biased	_
60-53	12032-12033	,	_
60-54	12034-12037	and	_
60-55	12038-12051	female-biased	_
60-56	12052-12057	genes	_
60-57	12058-12059	.	_

61-1	12060-12081	miR-gene-TF-targeting	_
61-2	12082-12083	:	_
61-3	12084-12090	miRNet	_
61-4	12091-12093	To	_
61-5	12094-12101	address	_
61-6	12102-12110	miR-mRNA	_
61-7	12111-12120	targeting	_
61-8	12121-12130	relations	_
61-9	12131-12132	,	_
61-10	12133-12135	we	_
61-11	12136-12145	developed	_
61-12	12146-12148	an	_
61-13	12149-12159	integrated	_
61-14	12160-12173	miR-targeting	_
61-15	12174-12179	graph	_
61-16	12180-12188	database	_
61-17	12189-12190	(	_
61-18	12191-12192	‘	_
61-19	12193-12199	miRNet	_
61-20	12200-12201	’	_
61-21	12202-12203	)	_
61-22	12204-12207	out	_
61-23	12208-12210	of	_
61-24	12211-12219	publicly	_
61-25	12220-12229	available	_
61-26	12230-12239	validated	_
61-27	12240-12243	and	_
61-28	12244-12253	predicted	_
61-29	12254-12258	data	_
61-30	12259-12260	,	_
61-31	12261-12273	implementing	_
61-32	12274-12275	a	_
61-33	12276-12283	scoring	_
61-34	12284-12290	system	_
61-35	12291-12298	derived	_
61-36	12299-12303	from	_
61-37	12304-12306	10	_
61-38	12307-12314	leading	_
61-39	12315-12325	prediction	_
61-40	12326-12336	algorithms	_
61-41	12337-12342	based	_
61-42	12343-12345	on	_
61-43	12346-12351	their	_
61-44	12352-12363	statistical	_
61-45	12364-12375	performance	_
61-46	12376-12378	at	_
61-47	12379-12382	the	_
61-48	12383-12395	whole-genome	_
61-49	12396-12401	level	_
61-50	12402-12403	.	_

62-1	12404-12406	To	_
62-2	12407-12417	facilitate	_
62-3	12418-12421	the	_
62-4	12422-12431	selection	_
62-5	12432-12439	process	_
62-6	12440-12441	,	_
62-7	12442-12451	targeting	_
62-8	12452-12456	data	_
62-9	12457-12461	were	_
62-10	12462-12471	cumulated	_
62-11	12472-12474	by	_
62-12	12475-12482	summing	_
62-13	12483-12486	the	_
62-14	12487-12493	amount	_
62-15	12494-12496	of	_
62-16	12497-12505	positive	_
62-17	12506-12507	“	_
62-18	12508-12512	hits	_
62-19	12513-12514	”	_
62-20	12515-12517	of	_
62-21	12518-12528	prediction	_
62-22	12529-12539	algorithms	_
62-23	12540-12541	(	_
62-24	12542-12543	1	_
62-25	12544-12549	point	_
62-26	12550-12551	)	_
62-27	12552-12555	and	_
62-28	12556-12564	positive	_
62-29	12565-12577	experimental	_
62-30	12578-12589	validations	_
62-31	12590-12591	(	_
62-32	12592-12596	only	_
62-33	12597-12598	“	_
62-34	12599-12605	strong	_
62-35	12606-12607	”	_
62-36	12608-12616	evidence	_
62-37	12617-12618	,	_
62-38	12619-12629	miRTarBase	_
62-39	12630-12631	,	_
62-40	12632-12636	10,5	_
62-41	12637-12643	points	_
62-42	12644-12645	)	_
62-43	12646-12648	of	_
62-44	12649-12652	the	_
62-45	12653-12662	targeting	_
62-46	12663-12675	relationship	_
62-47	12676-12677	,	_
62-48	12678-12686	yielding	_
62-49	12687-12688	a	_
62-50	12689-12698	targeting	_
62-51	12699-12704	score	_
62-52	12705-12712	between	_
62-53	12713-12714	0	_
62-54	12715-12718	and	_
62-55	12719-12723	20,5	_
62-56	12724-12725	.	_

63-1	12726-12728	We	_
63-2	12729-12734	found	_
63-3	12735-12736	a	_
63-4	12737-12744	minimal	_
63-5	12745-12750	score	_
63-6	12751-12753	of	_
63-7	12754-12755	6	_
63-8	12756-12758	to	_
63-9	12759-12766	suffice	_
63-10	12767-12770	for	_
63-11	12771-12772	a	_
63-12	12773-12777	good	_
63-13	12778-12785	balance	_
63-14	12786-12793	between	_
63-15	12794-12798	type	_
63-16	12799-12800	I	_
63-17	12801-12804	and	_
63-18	12805-12807	II	_
63-19	12808-12814	errors	_
63-20	12815-12816	.	_

64-1	12817-12819	In	_
64-2	12820-12824	case	_
64-3	12825-12827	of	_
64-4	12828-12840	whole-genome	_
64-5	12841-12853	interactions	_
64-6	12854-12855	,	_
64-7	12856-12860	this	_
64-8	12861-12870	threshold	_
64-9	12871-12874	was	_
64-10	12875-12881	raised	_
64-11	12882-12884	to	_
64-12	12885-12886	7	_
64-13	12887-12889	to	_
64-14	12890-12896	enable	_
64-15	12897-12910	computational	_
64-16	12911-12924	accessibility	_
64-17	12925-12927	in	_
64-18	12928-12931	all	_
64-19	12932-12937	steps	_
64-20	12938-12939	(	_
64-21	12940-12942	in	_
64-22	12943-12947	this	_
64-23	12948-12952	case	_
64-24	12953-12954	,	_
64-25	12955-12964	graphical	_
64-26	12965-12973	analysis	_
64-27	12974-12977	was	_
64-28	12978-12981	the	_
64-29	12982-12992	bottleneck	_
64-30	12993-12994	)	_
64-31	12995-12996	.	_

65-1	12997-13000	The	_
65-2	13001-13009	database	_
65-3	13010-13013	was	_
65-4	13014-13026	supplemented	_
65-5	13027-13029	by	_
65-6	13030-13043	comprehensive	_
65-7	13044-13057	transcription	_
65-8	13058-13064	factor	_
65-9	13065-13074	targeting	_
65-10	13075-13079	data	_
65-11	13080-13083	via	_
65-12	13084-13101	bioinformatically	_
65-13	13102-13111	processed	_
65-14	13112-13113	“	_
65-15	13114-13117	cap	_
65-16	13118-13126	analysis	_
65-17	13127-13129	of	_
65-18	13130-13134	gene	_
65-19	13135-13145	expression	_
65-20	13146-13147	”	_
65-21	13148-13149	(	_
65-22	13150-13154	CAGE	_
65-23	13155-13156	)	_
65-24	13157-13158	,	_
65-25	13159-13167	focusing	_
65-26	13168-13170	on	_
65-27	13171-13176	brain	_
65-28	13177-13184	tissues	_
65-29	13185-13186	,	_
65-30	13187-13196	including	_
65-31	13197-13200	the	_
65-32	13201-13216	tissue-specific	_
65-33	13217-13232	transcriptional	_
65-34	13233-13243	activities	_
65-35	13244-13245	(	_
65-36	13246-13252	Figure	_
65-37	13253-13255	S5	_
65-38	13256-13257	)	_
65-39	13258-13259	.	_

66-1	13260-13263	The	_
66-2	13264-13268	code	_
66-3	13269-13273	used	_
66-4	13274-13276	to	_
66-5	13277-13283	create	_
66-6	13284-13287	and	_
66-7	13288-13292	test	_
66-8	13293-13297	this	_
66-9	13298-13306	database	_
66-10	13307-13309	is	_
66-11	13310-13319	available	_
66-12	13320-13322	in	_
66-13	13323-13326	the	_
66-14	13327-13339	accompanying	_
66-15	13340-13350	repository	_
66-16	13351-13352	.	_

67-1	13353-13354	A	_
67-2	13355-13361	public	_
67-3	13362-13369	release	_
67-4	13370-13372	is	_
67-5	13373-13380	planned	_
67-6	13381-13382	,	_
67-7	13383-13386	but	_
67-8	13387-13390	not	_
67-9	13391-13400	completed	_
67-10	13401-13403	at	_
67-11	13404-13407	the	_
67-12	13408-13414	moment	_
67-13	13415-13416	;	_
67-14	13417-13425	requests	_
67-15	13426-13429	can	_
67-16	13430-13432	be	_
67-17	13433-13441	directed	_
67-18	13442-13444	at	_
67-19	13445-13448	the	_
67-20	13449-13462	corresponding	_
67-21	13463-13469	author	_
67-22	13470-13471	.	_

68-1	13472-13480	Analyses	_
68-2	13481-13490	performed	_
68-3	13491-13496	using	_
68-4	13497-13501	this	_
68-5	13502-13510	database	_
68-6	13511-13515	were	_
68-7	13516-13527	implemented	_
68-8	13528-13530	in	_
68-9	13531-13532	R	_
68-10	13533-13538	using	_
68-11	13539-13542	the	_
68-12	13543-13544	‘	_
68-13	13545-13551	RNeo4j	_
68-14	13552-13553	’	_
68-15	13554-13561	package	_
68-16	13562-13563	.	_

69-1	13564-13575	Limitations	_
69-2	13576-13583	Through	_
69-3	13584-13590	recent	_
69-4	13591-13601	methodical	_
69-5	13602-13605	and	_
69-6	13606-13621	bioinformatical	_
69-7	13622-13630	advances	_
69-8	13631-13632	,	_
69-9	13633-13642	targeting	_
69-10	13643-13647	data	_
69-11	13648-13650	of	_
69-12	13651-13664	transcription	_
69-13	13665-13672	factors	_
69-14	13673-13676	and	_
69-15	13677-13681	miRs	_
69-16	13682-13685	has	_
69-17	13686-13692	become	_
69-18	13693-13706	comprehensive	_
69-19	13707-13708	.	_

70-1	13709-13716	However	_
70-2	13717-13718	,	_
70-3	13719-13724	these	_
70-4	13725-13726	“	_
70-5	13727-13735	complete	_
70-6	13736-13737	”	_
70-7	13738-13746	datasets	_
70-8	13747-13750	are	_
70-9	13751-13758	subject	_
70-10	13759-13761	to	_
70-11	13762-13773	limitations	_
70-12	13774-13781	derived	_
70-13	13782-13786	from	_
70-14	13787-13790	the	_
70-15	13791-13798	methods	_
70-16	13799-13803	used	_
70-17	13804-13806	to	_
70-18	13807-13817	accumulate	_
70-19	13818-13821	raw	_
70-20	13822-13826	data	_
70-21	13827-13828	.	_

71-1	13829-13832	For	_
71-2	13833-13845	TF-targeting	_
71-3	13846-13847	,	_
71-4	13848-13852	CAGE	_
71-5	13853-13855	5′	_
71-6	13856-13861	peaks	_
71-7	13862-13866	were	_
71-8	13867-13875	analyzed	_
71-9	13876-13882	toward	_
71-10	13883-13888	their	_
71-11	13889-13900	correlation	_
71-12	13901-13905	with	_
71-13	13906-13910	gene	_
71-14	13911-13921	expression	_
71-15	13922-13924	in	_
71-16	13925-13928	all	_
71-17	13929-13938	available	_
71-18	13939-13946	tissues	_
71-19	13947-13948	.	_

72-1	13949-13950	A	_
72-2	13951-13962	cholinergic	_
72-3	13963-13970	example	_
72-4	13971-13973	of	_
72-5	13974-13985	limitations	_
72-6	13986-13993	derived	_
72-7	13994-13998	from	_
72-8	13999-14003	this	_
72-9	14004-14008	data	_
72-10	14009-14017	involves	_
72-11	14018-14021	the	_
72-12	14022-14026	CHAT	_
72-13	14027-14031	gene	_
72-14	14032-14033	,	_
72-15	14034-14039	which	_
72-16	14040-14044	does	_
72-17	14045-14048	not	_
72-18	14049-14056	provide	_
72-19	14057-14058	a	_
72-20	14059-14069	measurable	_
72-21	14070-14074	CAGE	_
72-22	14075-14079	peak	_
72-23	14080-14081	,	_
72-24	14082-14089	leading	_
72-25	14090-14092	to	_
72-26	14093-14111	non-representation	_
72-27	14112-14114	in	_
72-28	14115-14118	the	_
72-29	14119-14128	targeting	_
72-30	14129-14136	dataset	_
72-31	14137-14138	.	_

73-1	14139-14141	In	_
73-2	14142-14147	those	_
73-3	14148-14153	cases	_
73-4	14154-14155	,	_
73-5	14156-14165	targeting	_
73-6	14166-14170	data	_
73-7	14171-14179	acquired	_
73-8	14180-14187	through	_
73-9	14188-14200	conventional	_
73-10	14201-14208	methods	_
73-11	14209-14213	have	_
73-12	14214-14216	to	_
73-13	14217-14219	be	_
73-14	14220-14231	substituted	_
73-15	14232-14233	,	_
73-16	14234-14237	but	_
73-17	14238-14242	this	_
73-18	14243-14246	can	_
73-19	14247-14250	not	_
73-20	14251-14253	be	_
73-21	14254-14260	easily	_
73-22	14261-14265	done	_
73-23	14266-14269	for	_
73-24	14270-14273	all	_
73-25	14274-14282	affected	_
73-26	14283-14288	genes	_
73-27	14289-14290	,	_
73-28	14291-14294	and	_
73-29	14295-14297	is	_
73-30	14298-14302	also	_
73-31	14303-14306	not	_
73-32	14307-14320	comprehensive	_
73-33	14321-14322	.	_

74-1	14323-14325	In	_
74-2	14326-14329	the	_
74-3	14330-14334	case	_
74-4	14335-14337	of	_
74-5	14338-14351	miR-targeting	_
74-6	14352-14353	,	_
74-7	14354-14363	validated	_
74-8	14364-14376	interactions	_
74-9	14377-14380	are	_
74-10	14381-14386	based	_
74-11	14387-14389	on	_
74-12	14390-14402	experimental	_
74-13	14403-14407	work	_
74-14	14408-14414	mainly	_
74-15	14415-14424	performed	_
74-16	14425-14427	on	_
74-17	14428-14435	rodents	_
74-18	14436-14437	,	_
74-19	14438-14445	leading	_
74-20	14446-14448	to	_
74-21	14449-14450	a	_
74-22	14451-14459	research	_
74-23	14460-14464	bias	_
74-24	14465-14471	toward	_
74-25	14472-14486	evolutionarily	_
74-26	14487-14496	conserved	_
74-27	14497-14501	miRs	_
74-28	14502-14503	.	_

75-1	14504-14520	Primate-specific	_
75-2	14521-14525	miRs	_
75-3	14526-14535	therefore	_
75-4	14536-14539	are	_
75-5	14540-14557	under-represented	_
75-6	14558-14559	,	_
75-7	14560-14562	at	_
75-8	14563-14568	least	_
75-9	14569-14571	in	_
75-10	14572-14581	validated	_
75-11	14582-14586	data	_
75-12	14587-14588	.	_

76-1	14589-14600	Permutation	_
76-2	14601-14610	Targeting	_
76-3	14611-14619	Analyses	_
76-4	14620-14622	In	_
76-5	14623-14626	the	_
76-6	14627-14634	current	_
76-7	14635-14640	state	_
76-8	14641-14643	of	_
76-9	14644-14657	comprehensive	_
76-10	14658-14662	data	_
76-11	14663-14665	on	_
76-12	14666-14674	miR-gene	_
76-13	14675-14676	(	_
76-14	14677-14680	and	_
76-15	14681-14688	TF-gene	_
76-16	14689-14690	)	_
76-17	14691-14700	targeting	_
76-18	14701-14702	,	_
76-19	14703-14705	no	_
76-20	14706-14716	statements	_
76-21	14717-14720	can	_
76-22	14721-14723	be	_
76-23	14724-14728	made	_
76-24	14729-14733	with	_
76-25	14734-14742	absolute	_
76-26	14743-14752	certainty	_
76-27	14753-14754	.	_

77-1	14755-14759	Thus	_
77-2	14760-14761	,	_
77-3	14762-14764	an	_
77-4	14765-14773	approach	_
77-5	14774-14779	which	_
77-6	14780-14789	considers	_
77-7	14790-14798	relative	_
77-8	14799-14807	measures	_
77-9	14808-14810	is	_
77-10	14811-14821	preferable	_
77-11	14822-14823	.	_

78-1	14824-14827	For	_
78-2	14828-14832	this	_
78-3	14833-14839	reason	_
78-4	14840-14841	,	_
78-5	14842-14850	whenever	_
78-6	14851-14877	whole-genome/whole-miRnome	_
78-7	14878-14887	targeting	_
78-8	14888-14891	was	_
78-9	14892-14901	concerned	_
78-10	14902-14903	,	_
78-11	14904-14906	we	_
78-12	14907-14915	employed	_
78-13	14916-14922	random	_
78-14	14923-14934	permutation	_
78-15	14935-14937	of	_
78-16	14938-14941	the	_
78-17	14942-14952	prediction	_
78-18	14953-14960	dataset	_
78-19	14961-14963	or	_
78-20	14964-14968	each	_
78-21	14969-14975	single	_
78-22	14976-14985	predicted	_
78-23	14986-14989	miR	_
78-24	14990-14997	against	_
78-25	14998-14999	a	_
78-26	15000-15010	randomized	_
78-27	15011-15021	background	_
78-28	15022-15024	of	_
78-29	15025-15028	the	_
78-30	15029-15033	same	_
78-31	15034-15038	size	_
78-32	15039-15041	as	_
78-33	15042-15045	the	_
78-34	15046-15054	original	_
78-35	15055-15058	set	_
78-36	15059-15060	(	_
78-37	15061-15065	also	_
78-38	15066-15077	considering	_
78-39	15078-15085	family-	_
78-40	15086-15089	and	_
78-41	15090-15113	precursor-relationships	_
78-42	15114-15115	)	_
78-43	15116-15117	.	_

79-1	15118-15121	The	_
79-2	15122-15131	resulting	_
79-3	15132-15136	null	_
79-4	15137-15149	distribution	_
79-5	15150-15156	yields	_
79-6	15157-15158	a	_
79-7	15159-15164	basis	_
79-8	15165-15168	for	_
79-9	15169-15182	determination	_
79-10	15183-15185	of	_
79-11	15186-15187	a	_
79-12	15188-15193	false	_
79-13	15194-15203	discovery	_
79-14	15204-15208	rate	_
79-15	15209-15210	.	_

80-1	15211-15228	Neurokine-Induced	_
80-2	15229-15233	miRs	_
80-3	15234-15237	and	_
80-4	15238-15241	the	_
80-5	15242-15263	Cholinergic/Neurokine	_
80-6	15264-15271	Pathway	_
80-7	15272-15276	Gene	_
80-8	15277-15284	targets	_
80-9	15285-15287	of	_
80-10	15288-15291	the	_
80-11	15292-15295	490	_
80-12	15296-15310	differentially	_
80-13	15311-15320	regulated	_
80-14	15321-15325	miRs	_
80-15	15326-15335	following	_
80-16	15336-15340	CNTF	_
80-17	15341-15349	exposure	_
80-18	15350-15354	were	_
80-19	15355-15365	determined	_
80-20	15366-15368	by	_
80-21	15369-15375	miRNet	_
80-22	15376-15381	query	_
80-23	15382-15383	(	_
80-24	15384-15393	targeting	_
80-25	15394-15399	score	_
80-26	15400-15407	minimum	_
80-27	15408-15410	of	_
80-28	15411-15412	6	_
80-29	15413-15414	)	_
80-30	15415-15416	.	_

81-1	15417-15420	The	_
81-2	15421-15425	full	_
81-3	15426-15433	network	_
81-4	15434-15435	,	_
81-5	15436-15446	originally	_
81-6	15447-15457	comprising	_
81-7	15458-15466	∼160,000	_
81-8	15467-15473	unique	_
81-9	15474-15487	relationships	_
81-10	15488-15489	,	_
81-11	15490-15493	was	_
81-12	15494-15505	re-filtered	_
81-13	15506-15508	by	_
81-14	15509-15516	raising	_
81-15	15517-15520	the	_
81-16	15521-15530	threshold	_
81-17	15531-15533	to	_
81-18	15534-15539	score	_
81-19	15540-15547	minimum	_
81-20	15548-15550	of	_
81-21	15551-15552	7	_
81-22	15553-15555	to	_
81-23	15556-15558	be	_
81-24	15559-15574	computationally	_
81-25	15575-15585	accessible	_
81-26	15586-15587	.	_

82-1	15588-15591	The	_
82-2	15592-15601	resulting	_
82-3	15602-15609	network	_
82-4	15610-15613	and	_
82-5	15614-15624	individual	_
82-6	15625-15647	miR-family-subnetworks	_
82-7	15648-15652	were	_
82-8	15653-15660	plotted	_
82-9	15661-15666	using	_
82-10	15667-15668	a	_
82-11	15669-15683	force-directed	_
82-12	15684-15690	layout	_
82-13	15691-15692	(	_
82-14	15693-15698	Force	_
82-15	15699-15704	Atlas	_
82-16	15705-15706	2	_
82-17	15707-15708	)	_
82-18	15709-15711	in	_
82-19	15712-15717	gephi	_
82-20	15718-15719	.	_

83-1	15720-15731	Single-Cell	_
83-2	15732-15742	Sequencing	_
83-3	15743-15750	Dataset	_
83-4	15751-15759	Analysis	_
83-5	15760-15763	and	_
83-6	15764-15775	Permutation	_
83-7	15776-15778	We	_
83-8	15779-15787	analyzed	_
83-9	15788-15789	4	_
83-10	15790-15803	web-available	_
83-11	15804-15812	datasets	_
83-12	15813-15815	of	_
83-13	15816-15821	brain	_
83-14	15822-15828	single	_
83-15	15829-15833	cell	_
83-16	15834-15838	gene	_
83-17	15839-15849	expression	_
83-18	15850-15853	for	_
83-19	15854-15863	neurokine	_
83-20	15864-15873	signaling	_
83-21	15874-15885	transcripts	_
83-22	15886-15888	in	_
83-23	15889-15900	cholinergic	_
83-24	15901-15908	neurons	_
83-25	15909-15910	,	_
83-26	15911-15921	identified	_
83-27	15922-15924	by	_
83-28	15925-15930	their	_
83-29	15931-15941	expression	_
83-30	15942-15944	of	_
83-31	15945-15948	the	_
83-32	15949-15965	ACh-synthesizing	_
83-33	15966-15972	enzyme	_
83-34	15973-15980	choline	_
83-35	15981-15998	acetyltransferase	_
83-36	15999-16000	(	_
83-37	16001-16005	ChAT	_
83-38	16006-16007	)	_
83-39	16008-16009	,	_
83-40	16010-16013	and	_
83-41	16014-16017	its	_
83-42	16018-16026	embedded	_
83-43	16027-16031	gene	_
83-44	16032-16040	encoding	_
83-45	16041-16044	the	_
83-46	16045-16054	vesicular	_
83-47	16055-16068	acetylcholine	_
83-48	16069-16080	transporter	_
83-49	16081-16088	SLC18A3	_
83-50	16089-16090	,	_
83-51	16091-16095	also	_
83-52	16096-16101	known	_
83-53	16102-16104	as	_
83-54	16105-16110	vAChT	_
83-55	16111-16112	.	_

84-1	16113-16116	Raw	_
84-2	16117-16121	gene	_
84-3	16122-16132	expression	_
84-4	16133-16137	data	_
84-5	16138-16142	were	_
84-6	16143-16153	normalized	_
84-7	16154-16157	and	_
84-8	16158-16162	then	_
84-9	16163-16172	clustered	_
84-10	16173-16176	and	_
84-11	16177-16184	plotted	_
84-12	16185-16188	via	_
84-13	16189-16199	R/pheatmap	_
84-14	16200-16201	.	_

85-1	16202-16205	The	_
85-2	16206-16211	genes	_
85-3	16212-16221	expressed	_
85-4	16222-16224	in	_
85-5	16225-16229	more	_
85-6	16230-16234	than	_
85-7	16235-16238	one	_
85-8	16239-16245	sample	_
85-9	16246-16249	per	_
85-10	16250-16257	dataset	_
85-11	16258-16262	were	_
85-12	16263-16271	enriched	_
85-13	16272-16275	for	_
85-14	16276-16285	targeting	_
85-15	16286-16288	of	_
85-16	16289-16292	TFs	_
85-17	16293-16296	and	_
85-18	16297-16301	miRs	_
85-19	16302-16304	by	_
85-20	16305-16311	random	_
85-21	16312-16323	permutation	_
85-22	16324-16332	analysis	_
85-23	16333-16334	(	_
85-24	16335-16338	via	_
85-25	16339-16345	miRNet	_
85-26	16346-16347	)	_
85-27	16348-16349	,	_
85-28	16350-16354	with	_
85-29	16355-16357	10	_
85-30	16358-16361	000	_
85-31	16362-16374	permutations	_
85-32	16375-16378	for	_
85-33	16379-16388	conserved	_
85-34	16389-16392	and	_
85-35	16393-16400	primate	_
85-36	16401-16411	miR-target	_
85-37	16412-16425	relationships	_
85-38	16426-16427	,	_
85-39	16428-16431	and	_
85-40	16432-16437	human	_
85-41	16438-16441	CNS	_
85-42	16442-16444	TF	_
85-43	16445-16457	interactions	_
85-44	16458-16459	.	_

86-1	16460-16466	Subset	_
86-2	16467-16475	Analyses	_
86-3	16476-16487	Cholinergic	_
86-4	16488-16493	Genes	_
86-5	16494-16495	,	_
86-6	16496-16509	Transcription	_
86-7	16510-16516	Factor	_
86-8	16517-16518	,	_
86-9	16519-16522	and	_
86-10	16523-16532	Neurokine	_
86-11	16533-16541	Analyses	_
86-12	16542-16544	To	_
86-13	16545-16551	follow	_
86-14	16552-16555	our	_
86-15	16556-16567	cholinergic	_
86-16	16568-16576	interest	_
86-17	16577-16578	,	_
86-18	16579-16581	we	_
86-19	16582-16586	used	_
86-20	16587-16588	a	_
86-21	16589-16595	recent	_
86-22	16596-16602	review	_
86-23	16603-16605	to	_
86-24	16606-16612	define	_
86-25	16613-16614	a	_
86-26	16615-16619	core	_
86-27	16620-16623	set	_
86-28	16624-16626	of	_
86-29	16627-16632	genes	_
86-30	16633-16634	,	_
86-31	16635-16641	adding	_
86-32	16642-16644	to	_
86-33	16645-16647	it	_
86-34	16648-16651	the	_
86-35	16652-16661	neurokine	_
86-36	16662-16665	and	_
86-37	16666-16675	circadian	_
86-38	16676-16683	pathway	_
86-39	16684-16689	genes	_
86-40	16690-16699	indicated	_
86-41	16700-16702	in	_
86-42	16703-16706	the	_
86-43	16707-16715	previous	_
86-44	16716-16724	analyses	_
86-45	16725-16726	(	_
86-46	16727-16729	to	_
86-47	16730-16731	a	_
86-48	16732-16737	total	_
86-49	16738-16740	of	_
86-50	16741-16743	76	_
86-51	16744-16749	genes	_
86-52	16750-16751	)	_
86-53	16752-16753	.	_

87-1	16754-16757	Via	_
87-2	16758-16764	miRNet	_
87-3	16765-16776	permutation	_
87-4	16777-16778	(	_
87-5	16779-16783	Data	_
87-6	16784-16786	S2	_
87-7	16787-16788	)	_
87-8	16789-16790	,	_
87-9	16791-16793	we	_
87-10	16794-16804	identified	_
87-11	16805-16807	18	_
87-12	16808-16823	brain-expressed	_
87-13	16824-16825	“	_
87-14	16826-16837	cholinergic	_
87-15	16838-16839	”	_
87-16	16840-16843	TFs	_
87-17	16844-16845	(	_
87-18	16846-16847	p	_
87-19	16848-16849	<	_
87-20	16850-16854	0.05	_
87-21	16855-16856	)	_
87-22	16857-16860	and	_
87-23	16861-16866	their	_
87-24	16867-16870	CNS	_
87-25	16871-16886	transcriptional	_
87-26	16887-16895	activity	_
87-27	16896-16902	toward	_
87-28	16903-16907	each	_
87-29	16908-16916	targeted	_
87-30	16917-16928	cholinergic	_
87-31	16929-16933	gene	_
87-32	16934-16935	.	_

88-1	16936-16941	These	_
88-2	16942-16944	94	_
88-3	16945-16950	genes	_
88-4	16951-16952	(	_
88-5	16953-16957	Data	_
88-6	16958-16960	S7	_
88-7	16961-16962	)	_
88-8	16963-16967	were	_
88-9	16968-16972	then	_
88-10	16973-16982	subjected	_
88-11	16983-16985	to	_
88-12	16986-16998	differential	_
88-13	16999-17009	expression	_
88-14	17010-17018	analysis	_
88-15	17019-17021	in	_
88-16	17022-17025	the	_
88-17	17026-17035	deposited	_
88-18	17036-17043	patient	_
88-19	17044-17052	datasets	_
88-20	17053-17054	.	_

89-1	17055-17064	Execution	_
89-2	17065-17067	of	_
89-3	17068-17074	Subset	_
89-4	17075-17083	Analyses	_
89-5	17084-17086	To	_
89-6	17087-17097	separately	_
89-7	17098-17105	analyze	_
89-8	17106-17110	male	_
89-9	17111-17114	and	_
89-10	17115-17121	female	_
89-11	17122-17126	data	_
89-12	17127-17129	in	_
89-13	17130-17133	the	_
89-14	17134-17142	original	_
89-15	17143-17151	datasets	_
89-16	17152-17153	,	_
89-17	17154-17156	we	_
89-18	17157-17165	repeated	_
89-19	17166-17169	the	_
89-20	17170-17185	sex-independent	_
89-21	17186-17194	analyses	_
89-22	17195-17197	of	_
89-23	17198-17201	the	_
89-24	17202-17212	identified	_
89-25	17213-17215	94	_
89-26	17216-17227	cholinergic	_
89-27	17228-17233	genes	_
89-28	17234-17237	and	_
89-29	17238-17241	TFs	_
89-30	17242-17247	using	_
89-31	17248-17251	the	_
89-32	17252-17257	limma	_
89-33	17258-17266	pipeline	_
89-34	17267-17268	.	_

90-1	17269-17283	Pre-processing	_
90-2	17284-17287	was	_
90-3	17288-17297	identical	_
90-4	17298-17300	to	_
90-5	17301-17304	the	_
90-6	17305-17324	whole-transcriptome	_
90-7	17325-17333	approach	_
90-8	17334-17335	,	_
90-9	17336-17339	and	_
90-10	17340-17347	dataset	_
90-11	17348-17357	reduction	_
90-12	17358-17366	involved	_
90-13	17367-17378	restricting	_
90-14	17379-17382	the	_
90-15	17383-17389	output	_
90-16	17390-17395	table	_
90-17	17396-17397	(	_
90-18	17398-17406	topTable	_
90-19	17407-17408	(	_
90-20	17409-17410	)	_
90-21	17411-17419	function	_
90-22	17420-17421	)	_
90-23	17422-17424	to	_
90-24	17425-17428	the	_
90-25	17429-17436	studied	_
90-26	17437-17442	genes	_
90-27	17443-17444	.	_

91-1	17445-17449	This	_
91-2	17450-17457	further	_
91-3	17458-17465	allowed	_
91-4	17466-17477	controlling	_
91-5	17478-17480	of	_
91-6	17481-17488	missing	_
91-7	17489-17494	genes	_
91-8	17495-17497	of	_
91-9	17498-17506	interest	_
91-10	17507-17509	by	_
91-11	17510-17518	manually	_
91-12	17519-17526	solving	_
91-13	17527-17535	problems	_
91-14	17536-17538	of	_
91-15	17539-17549	annotation	_
91-16	17550-17551	,	_
91-17	17552-17557	which	_
91-18	17558-17560	in	_
91-19	17561-17562	a	_
91-20	17563-17575	whole-genome	_
91-21	17576-17584	analysis	_
91-22	17585-17590	would	_
91-23	17591-17595	have	_
91-24	17596-17599	led	_
91-25	17600-17602	to	_
91-26	17603-17607	loss	_
91-27	17608-17610	of	_
91-28	17611-17622	information	_
91-29	17623-17625	on	_
91-30	17626-17627	,	_
91-31	17628-17632	e.g.	_
91-32	17633-17634	,	_
91-33	17635-17638	the	_
91-34	17639-17648	nicotinic	_
91-35	17649-17651	α7	_
91-36	17652-17655	and	_
91-37	17656-17673	stress-responding	_
91-38	17674-17676	M1	_
91-39	17677-17688	cholinergic	_
91-40	17689-17698	receptors	_
91-41	17699-17700	.	_

92-1	17701-17712	miR-125b-5p	_
92-2	17713-17723	Validation	_
92-3	17724-17726	To	_
92-4	17727-17731	test	_
92-5	17732-17739	binding	_
92-6	17740-17742	of	_
92-7	17743-17758	hsa-miR-125b-5p	_
92-8	17759-17761	to	_
92-9	17762-17765	the	_
92-10	17766-17786	acetylcholinesterase	_
92-11	17787-17788	(	_
92-12	17789-17793	AChE	_
92-13	17794-17795	)	_
92-14	17796-17802	3′-UTR	_
92-15	17803-17804	,	_
92-16	17805-17807	we	_
92-17	17808-17817	performed	_
92-18	17818-17830	vector-based	_
92-19	17831-17837	assays	_
92-20	17838-17841	via	_
92-21	17842-17853	suppression	_
92-22	17854-17856	of	_
92-23	17857-17858	a	_
92-24	17859-17868	cytotoxic	_
92-25	17869-17875	sensor	_
92-26	17876-17878	as	_
92-27	17879-17883	well	_
92-28	17884-17886	as	_
92-29	17887-17889	of	_
92-30	17890-17897	Renilla	_
92-31	17898-17908	luciferase	_
92-32	17909-17910	,	_
92-33	17911-17915	both	_
92-34	17916-17921	fused	_
92-35	17922-17924	to	_
92-36	17925-17928	the	_
92-37	17929-17940	AChE-3′-UTR	_
92-38	17941-17942	.	_

93-1	17943-17950	Briefly	_
93-2	17951-17952	,	_
93-3	17953-17956	the	_
93-4	17957-17959	3′	_
93-5	17960-17972	untranslated	_
93-6	17973-17979	region	_
93-7	17980-17981	(	_
93-8	17982-17988	3′-UTR	_
93-9	17989-17990	)	_
93-10	17991-17993	of	_
93-11	17994-17999	human	_
93-12	18000-18004	AChE	_
93-13	18005-18009	mRNA	_
93-14	18010-18013	was	_
93-15	18014-18020	cloned	_
93-16	18021-18025	into	_
93-17	18026-18029	the	_
93-18	18030-18038	microRNA	_
93-19	18039-18045	Target	_
93-20	18046-18055	Selection	_
93-21	18056-18062	System	_
93-22	18063-18070	plasmid	_
93-23	18071-18072	(	_
93-24	18073-18079	System	_
93-25	18080-18091	Biosciences	_
93-26	18092-18093	,	_
93-27	18094-18096	CA	_
93-28	18097-18098	,	_
93-29	18099-18102	USA	_
93-30	18103-18104	)	_
93-31	18105-18113	multiple	_
93-32	18114-18121	cloning	_
93-33	18122-18126	site	_
93-34	18127-18128	,	_
93-35	18129-18134	using	_
93-36	18135-18140	EcoRI	_
93-37	18141-18144	and	_
93-38	18145-18149	NotI	_
93-39	18150-18161	restriction	_
93-40	18162-18169	enzymes	_
93-41	18170-18171	(	_
93-42	18172-18175	New	_
93-43	18176-18183	England	_
93-44	18184-18191	Biolabs	_
93-45	18192-18193	)	_
93-46	18194-18195	.	_

94-1	18196-18199	All	_
94-2	18200-18208	plasmids	_
94-3	18209-18213	were	_
94-4	18214-18222	verified	_
94-5	18223-18225	by	_
94-6	18226-18229	DNA	_
94-7	18230-18240	sequencing	_
94-8	18241-18242	.	_

95-1	18243-18246	For	_
95-2	18247-18257	luciferase	_
95-3	18258-18264	assays	_
95-4	18265-18266	,	_
95-5	18267-18274	HEK293T	_
95-6	18275-18280	cells	_
95-7	18281-18285	were	_
95-8	18286-18297	transfected	_
95-9	18298-18302	with	_
95-10	18303-18308	miRNA	_
95-11	18309-18315	Target	_
95-12	18316-18336	Selection-AChE-3′UTR	_
95-13	18337-18338	,	_
95-14	18339-18342	and	_
95-15	18343-18351	selected	_
95-16	18352-18354	in	_
95-17	18355-18358	the	_
95-18	18359-18367	presence	_
95-19	18368-18370	of	_
95-20	18371-18380	Puromycin	_
95-21	18381-18384	for	_
95-22	18385-18386	3	_
95-23	18387-18392	weeks	_
95-24	18393-18394	.	_

96-1	18395-18401	Stably	_
96-2	18402-18413	transfected	_
96-3	18414-18421	HEK293T	_
96-4	18422-18423	(	_
96-5	18424-18433	293T-AChE	_
96-6	18434-18439	3′UTR	_
96-7	18440-18441	)	_
96-8	18442-18447	cells	_
96-9	18448-18452	were	_
96-10	18453-18458	grown	_
96-11	18459-18461	on	_
96-12	18462-18469	12-well	_
96-13	18470-18476	plates	_
96-14	18477-18480	and	_
96-15	18481-18489	infected	_
96-16	18490-18494	with	_
96-17	18495-18507	lentiviruses	_
96-18	18508-18518	expressing	_
96-19	18519-18530	miR-125b-5p	_
96-20	18531-18532	,	_
96-21	18533-18543	miR-132-3p	_
96-22	18544-18546	or	_
96-23	18547-18548	a	_
96-24	18549-18557	negative	_
96-25	18558-18565	control	_
96-26	18566-18574	sequence	_
96-27	18575-18576	.	_

97-1	18577-18582	After	_
97-2	18583-18585	48	_
97-3	18586-18591	hours	_
97-4	18592-18602	incubation	_
97-5	18603-18604	,	_
97-6	18605-18610	cells	_
97-7	18611-18615	were	_
97-8	18616-18624	analyzed	_
97-9	18625-18630	using	_
97-10	18631-18634	the	_
97-11	18635-18639	Dual	_
97-12	18640-18650	Luciferase	_
97-13	18651-18656	Assay	_
97-14	18657-18660	kit	_
97-15	18661-18662	(	_
97-16	18663-18670	Promega	_
97-17	18671-18672	,	_
97-18	18673-18675	WI	_
97-19	18676-18679	USA	_
97-20	18680-18681	)	_
97-21	18682-18685	and	_
97-22	18686-18696	Luciferase	_
97-23	18697-18705	activity	_
97-24	18706-18709	was	_
97-25	18710-18718	measured	_
97-26	18719-18724	using	_
97-27	18725-18727	an	_
97-28	18728-18736	Envision	_
97-29	18737-18748	luminescent	_
97-30	18749-18754	plate	_
97-31	18755-18761	reader	_
97-32	18762-18763	(	_
97-33	18764-18776	Perkin-Elmer	_
97-34	18777-18778	,	_
97-35	18779-18786	Waltham	_
97-36	18787-18788	,	_
97-37	18789-18791	MA	_
97-38	18792-18793	)	_
97-39	18794-18795	,	_
97-40	18796-18807	essentially	_
97-41	18808-18810	as	_
97-42	18811-18821	previously	_
97-43	18822-18831	described	_
97-44	18832-18833	.	_

98-1	18834-18837	For	_
98-2	18838-18842	each	_
98-3	18843-18851	reporter	_
98-4	18852-18861	construct	_
98-5	18862-18863	,	_
98-6	18864-18871	renilla	_
98-7	18872-18882	luciferase	_
98-8	18883-18891	activity	_
98-9	18892-18895	was	_
98-10	18896-18906	normalized	_
98-11	18907-18916	according	_
98-12	18917-18919	to	_
98-13	18920-18924	that	_
98-14	18925-18927	of	_
98-15	18928-18931	the	_
98-16	18932-18939	firefly	_
98-17	18940-18941	.	_

99-1	18942-18952	Normalized	_
99-2	18953-18961	activity	_
99-3	18962-18967	after	_
99-4	18968-18977	infection	_
99-5	18978-18980	of	_
99-6	18981-18991	miR-132-3p	_
99-7	18992-18994	or	_
99-8	18995-19006	miR-125b-5p	_
99-9	19007-19010	was	_
99-10	19011-19020	expressed	_
99-11	19021-19023	as	_
99-12	19024-19032	relative	_
99-13	19033-19035	to	_
99-14	19036-19040	that	_
99-15	19041-19049	obtained	_
99-16	19050-19055	after	_
99-17	19056-19065	infection	_
99-18	19066-19070	with	_
99-19	19071-19074	the	_
99-20	19075-19079	same	_
99-21	19080-19087	plasmid	_
99-22	19088-19092	with	_
99-23	19093-19096	miR	_
99-24	19097-19105	negative	_
99-25	19106-19113	control	_
99-26	19114-19115	.	_

100-1	19116-19119	For	_
100-2	19120-19130	life/death	_
100-3	19131-19136	assay	_
100-4	19137-19138	,	_
100-5	19139-19140	a	_
100-6	19141-19148	similar	_
100-7	19149-19157	protocol	_
100-8	19158-19161	was	_
100-9	19162-19166	used	_
100-10	19167-19168	.	_

101-1	19169-19175	Stably	_
101-2	19176-19187	transfected	_
101-3	19188-19195	HEK293T	_
101-4	19196-19197	(	_
101-5	19198-19207	293T-AChE	_
101-6	19208-19213	3′UTR	_
101-7	19214-19215	)	_
101-8	19216-19221	cells	_
101-9	19222-19226	were	_
101-10	19227-19235	infected	_
101-11	19236-19240	with	_
101-12	19241-19253	lentiviruses	_
101-13	19254-19264	expressing	_
101-14	19265-19276	miR-125b-5p	_
101-15	19277-19278	,	_
101-16	19279-19289	miR-132-3p	_
101-17	19290-19292	or	_
101-18	19293-19294	a	_
101-19	19295-19303	negative	_
101-20	19304-19311	control	_
101-21	19312-19320	sequence	_
101-22	19321-19322	.	_

102-1	19323-19325	72	_
102-2	19326-19331	hours	_
102-3	19332-19346	post-infection	_
102-4	19347-19348	a	_
102-5	19349-19358	cytotoxic	_
102-6	19359-19367	reporter	_
102-7	19368-19373	fused	_
102-8	19374-19376	to	_
102-9	19377-19381	AChE	_
102-10	19382-19388	3′-UTR	_
102-11	19389-19392	was	_
102-12	19393-19398	added	_
102-13	19399-19401	to	_
102-14	19402-19405	the	_
102-15	19406-19411	media	_
102-16	19412-19415	and	_
102-17	19416-19421	cells	_
102-18	19422-19426	were	_
102-19	19427-19431	kept	_
102-20	19432-19435	for	_
102-21	19436-19438	an	_
102-22	19439-19449	additional	_
102-23	19450-19451	5	_
102-24	19452-19456	days	_
102-25	19457-19459	to	_
102-26	19460-19466	assess	_
102-27	19467-19472	their	_
102-28	19473-19482	viability	_
102-29	19483-19484	.	_

103-1	19485-19496	Statistical	_
103-2	19497-19509	significance	_
103-3	19510-19513	was	_
103-4	19514-19524	determined	_
103-5	19525-19530	using	_
103-6	19531-19536	ANOVA	_
103-7	19537-19541	with	_
103-8	19542-19552	correction	_
103-9	19553-19556	for	_
103-10	19557-19565	multiple	_
103-11	19566-19573	testing	_
103-12	19574-19575	.	_

104-1	19576-19578	To	_
104-2	19579-19583	show	_
104-3	19584-19591	effects	_
104-4	19592-19594	of	_
104-5	19595-19602	changes	_
104-6	19603-19605	in	_
104-7	19606-19610	this	_
104-8	19611-19614	miR	_
104-9	19615-19616	’	_
104-10	19617-19618	s	_
104-11	19619-19625	levels	_
104-12	19626-19628	on	_
104-13	19629-19638	real-life	_
104-14	19639-19646	protein	_
104-15	19647-19657	activities	_
104-16	19658-19659	,	_
104-17	19660-19662	we	_
104-18	19663-19672	performed	_
104-19	19673-19675	an	_
104-20	19676-19680	AChE	_
104-21	19681-19691	hydrolytic	_
104-22	19692-19700	activity	_
104-23	19701-19706	assay	_
104-24	19707-19716	following	_
104-25	19717-19726	infection	_
104-26	19727-19729	of	_
104-27	19730-19735	human	_
104-28	19736-19749	monocyte-like	_
104-29	19750-19754	U937	_
104-30	19755-19760	cells	_
104-31	19761-19765	with	_
104-32	19766-19781	hsa-miR-125b-5p	_
104-33	19782-19783	,	_
104-34	19784-19794	miR-132-3p	_
104-35	19795-19797	or	_
104-36	19798-19799	a	_
104-37	19800-19808	negative	_
104-38	19809-19816	control	_
104-39	19817-19827	lentiviral	_
104-40	19828-19834	vector	_
104-41	19835-19836	.	_

105-1	19837-19841	AChE	_
105-2	19842-19852	hydrolytic	_
105-3	19853-19861	activity	_
105-4	19862-19868	levels	_
105-5	19869-19873	were	_
105-6	19874-19882	assessed	_
105-7	19883-19885	by	_
105-8	19886-19893	kinetic	_
105-9	19894-19906	measurements	_
105-10	19907-19909	of	_
105-11	19910-19913	the	_
105-12	19914-19924	hydrolysis	_
105-13	19925-19930	rates	_
105-14	19931-19933	of	_
105-15	19934-19935	1	_
105-16	19936-19938	mM	_
105-17	19939-19956	acetylthiocholine	_
105-18	19957-19958	(	_
105-19	19959-19963	ATCh	_
105-20	19964-19965	,	_
105-21	19966-19971	Sigma	_
105-22	19972-19973	)	_
105-23	19974-19976	at	_
105-24	19977-19981	room	_
105-25	19982-19993	temperature	_
105-26	19994-19995	,	_
105-27	19996-20005	following	_
105-28	20006-20008	20	_
105-29	20009-20012	min	_
105-30	20013-20023	incubation	_
105-31	20024-20028	with	_
105-32	20029-20032	and	_
105-33	20033-20040	without	_
105-34	20041-20047	5x10−5	_
105-35	20048-20049	M	_
105-36	20050-20064	tetraisopropyl	_
105-37	20065-20082	pyrophosphoramide	_
105-38	20083-20084	(	_
105-39	20085-20093	iso-OMPA	_
105-40	20094-20095	,	_
105-41	20096-20101	Sigma	_
105-42	20102-20103	)	_
105-43	20104-20105	,	_
105-44	20106-20107	a	_
105-45	20108-20116	specific	_
105-46	20117-20126	inhibitor	_
105-47	20127-20129	of	_
105-48	20130-20151	butyrylcholinesterase	_
105-49	20152-20153	,	_
105-50	20154-20156	to	_
105-51	20157-20168	selectively	_
105-52	20169-20174	assay	_
105-53	20175-20178	for	_
105-54	20179-20192	AChE-specific	_
105-55	20193-20195	or	_
105-56	20196-20201	total	_
105-57	20202-20216	cholinesterase	_
105-58	20217-20225	activity	_
105-59	20226-20227	.	_

106-1	20228-20232	Each	_
106-2	20233-20239	sample	_
106-3	20240-20243	was	_
106-4	20244-20251	assayed	_
106-5	20252-20254	in	_
106-6	20255-20257	at	_
106-7	20258-20263	least	_
106-8	20264-20265	3	_
106-9	20266-20276	biological	_
106-10	20277-20287	replicates	_
106-11	20288-20289	.	_

107-1	20290-20292	In	_
107-2	20293-20296	all	_
107-3	20297-20302	cases	_
107-4	20303-20304	,	_
107-5	20305-20319	hsa-miR-132-3p	_
107-6	20320-20326	served	_
107-7	20327-20329	as	_
107-8	20330-20331	a	_
107-9	20332-20340	positive	_
107-10	20341-20348	control	_
107-11	20349-20350	.	_

108-1	20351-20365	Quantification	_
108-2	20366-20369	and	_
108-3	20370-20381	Statistical	_
108-4	20382-20390	Analysis	_
108-5	20391-20402	Statistical	_
108-6	20403-20411	analyses	_
108-7	20412-20416	were	_
108-8	20417-20426	performed	_
108-9	20427-20429	in	_
108-10	20430-20432	R.	_
108-11	20433-20438	Small	_
108-12	20439-20443	sets	_
108-13	20444-20446	of	_
108-14	20447-20457	continuous	_
108-15	20458-20467	variables	_
108-16	20468-20469	,	_
108-17	20470-20474	such	_
108-18	20475-20477	as	_
108-19	20478-20482	qPCR	_
108-20	20483-20486	and	_
108-21	20487-20498	miR-125b-5p	_
108-22	20499-20509	validation	_
108-23	20510-20521	experiments	_
108-24	20522-20523	,	_
108-25	20524-20528	were	_
108-26	20529-20535	tested	_
108-27	20536-20541	using	_
108-28	20542-20547	Welch	_
108-29	20548-20549	’	_
108-30	20550-20551	s	_
108-31	20552-20555	Two	_
108-32	20556-20562	Sample	_
108-33	20563-20564	t	_
108-34	20565-20569	test	_
108-35	20570-20571	(	_
108-36	20572-20579	because	_
108-37	20580-20582	in	_
108-38	20583-20587	most	_
108-39	20588-20593	cases	_
108-40	20594-20595	,	_
108-41	20596-20601	equal	_
108-42	20602-20610	variance	_
108-43	20611-20616	could	_
108-44	20617-20620	not	_
108-45	20621-20623	be	_
108-46	20624-20631	assumed	_
108-47	20632-20633	;	_
108-48	20634-20642	R/t.test	_
108-49	20643-20644	)	_
108-50	20645-20648	and	_
108-51	20649-20654	ANOVA	_
108-52	20655-20656	;	_
108-53	20657-20668	statistical	_
108-54	20669-20681	significance	_
108-55	20682-20685	was	_
108-56	20686-20693	assumed	_
108-57	20694-20696	at	_
108-58	20697-20698	p	_
108-59	20699-20700	<	_
108-60	20701-20705	0.05	_
108-61	20706-20707	.	_

109-1	20708-20711	For	_
109-2	20712-20722	sequencing	_
109-3	20723-20728	count	_
109-4	20729-20733	data	_
109-5	20734-20735	,	_
109-6	20736-20739	the	_
109-7	20740-20748	negative	_
109-8	20749-20757	binomial	_
109-9	20758-20769	generalized	_
109-10	20770-20776	linear	_
109-11	20777-20782	model	_
109-12	20783-20786	was	_
109-13	20787-20793	tested	_
109-14	20794-20799	using	_
109-15	20800-20803	the	_
109-16	20804-20812	R/DESeq2	_
109-17	20813-20820	package	_
109-18	20821-20822	(	_
109-19	20823-20824	“	_
109-20	20825-20829	Wald	_
109-21	20830-20831	”	_
109-22	20832-20836	test	_
109-23	20837-20846	including	_
109-24	20847-20855	log-fold	_
109-25	20856-20862	change	_
109-26	20863-20872	shrinkage	_
109-27	20873-20874	)	_
109-28	20875-20877	to	_
109-29	20878-20884	detect	_
109-30	20885-20899	differentially	_
109-31	20900-20909	expressed	_
109-32	20910-20914	miRs	_
109-33	20915-20916	,	_
109-34	20917-20922	using	_
109-35	20923-20926	the	_
109-36	20927-20935	supplied	_
109-37	20936-20947	independent	_
109-38	20948-20957	filtering	_
109-39	20958-20961	and	_
109-40	20962-20972	correction	_
109-41	20973-20976	for	_
109-42	20977-20985	multiple	_
109-43	20986-20993	testing	_
109-44	20994-20996	at	_
109-45	20997-20999	an	_
109-46	21000-21005	alpha	_
109-47	21006-21011	level	_
109-48	21012-21014	of	_
109-49	21015-21018	0.1	_
109-50	21019-21020	.	_

110-1	21021-21023	In	_
110-2	21024-21029	cases	_
110-3	21030-21035	where	_
110-4	21036-21046	additional	_
110-5	21047-21052	power	_
110-6	21053-21056	was	_
110-7	21057-21066	desirable	_
110-8	21067-21069	or	_
110-9	21070-21071	p	_
110-10	21072-21078	values	_
110-11	21079-21084	could	_
110-12	21085-21088	not	_
110-13	21089-21091	be	_
110-14	21092-21100	obtained	_
110-15	21101-21103	by	_
110-16	21104-21109	other	_
110-17	21110-21115	means	_
110-18	21116-21117	(	_
110-19	21118-21131	transcriptome	_
110-20	21132-21145	meta-analysis	_
110-21	21146-21147	,	_
110-22	21148-21153	whole	_
110-23	21154-21160	genome	_
110-24	21161-21174	miR-targeting	_
110-25	21175-21176	)	_
110-26	21177-21178	,	_
110-27	21179-21190	permutation	_
110-28	21191-21199	analysis	_
110-29	21200-21203	was	_
110-30	21204-21213	performed	_
110-31	21214-21215	.	_

111-1	21216-21220	This	_
111-2	21221-21230	comprised	_
111-3	21231-21237	random	_
111-4	21238-21248	assignment	_
111-5	21249-21251	of	_
111-6	21252-21256	test	_
111-7	21257-21266	variables	_
111-8	21267-21269	in	_
111-9	21270-21273	the	_
111-10	21274-21278	same	_
111-11	21279-21283	size	_
111-12	21284-21286	as	_
111-13	21287-21290	the	_
111-14	21291-21299	original	_
111-15	21300-21304	test	_
111-16	21305-21308	set	_
111-17	21309-21312	and	_
111-18	21313-21322	repeating	_
111-19	21323-21326	the	_
111-20	21327-21335	analysis	_
111-21	21336-21339	for	_
111-22	21340-21341	a	_
111-23	21342-21347	large	_
111-24	21348-21354	number	_
111-25	21355-21357	of	_
111-26	21358-21363	times	_
111-27	21364-21365	,	_
111-28	21366-21370	such	_
111-29	21371-21375	that	_
111-30	21376-21377	a	_
111-31	21378-21382	null	_
111-32	21383-21395	distribution	_
111-33	21396-21398	of	_
111-34	21399-21405	values	_
111-35	21406-21411	could	_
111-36	21412-21414	be	_
111-37	21415-21424	generated	_
111-38	21425-21426	,	_
111-39	21427-21432	which	_
111-40	21433-21436	can	_
111-41	21437-21439	be	_
111-42	21440-21444	used	_
111-43	21445-21447	to	_
111-44	21448-21457	determine	_
111-45	21458-21459	a	_
111-46	21460-21465	false	_
111-47	21466-21475	discovery	_
111-48	21476-21481	ratio	_
111-49	21482-21485	for	_
111-50	21486-21489	the	_
111-51	21490-21498	original	_
111-52	21499-21505	result	_
111-53	21506-21507	.	_

112-1	21508-21519	Statistical	_
112-2	21520-21532	significance	_
112-3	21533-21536	was	_
112-4	21537-21544	assumed	_
112-5	21545-21547	at	_
112-6	21548-21549	p	_
112-7	21550-21551	<	_
112-8	21552-21557	0.05.	_
112-9	21558-21562	qPCR	_
112-10	21563-21565	of	_
112-11	21566-21576	ChAT/vAChT	_
112-12	21577-21581	mRNA	_
112-13	21582-21589	against	_
112-14	21590-21602	housekeeping	_
112-15	21603-21605	in	_
112-16	21606-21612	LA-N-2	_
112-17	21613-21614	,	_
112-18	21615-21616	p	_
112-19	21617-21623	values	_
112-20	21624-21627	are	_
112-21	21628-21633	found	_
112-22	21634-21636	in	_
112-23	21637-21644	Results	_
112-24	21645-21646	(	_
112-25	21647-21652	Welch	_
112-26	21653-21663	two-sample	_
112-27	21664-21665	t	_
112-28	21666-21670	test	_
112-29	21671-21672	)	_
112-30	21673-21674	:	_
112-31	21675-21679	Chat	_
112-32	21680-21681	,	_
112-33	21682-21685	Day	_
112-34	21686-21687	2	_
112-35	21688-21689	,	_
112-36	21690-21692	10	_
112-37	21693-21698	ng/ml	_
112-38	21699-21700	,	_
112-39	21701-21702	t	_
112-40	21703-21704	=	_
112-41	21705-21712	−3.2436	_
112-42	21713-21714	,	_
112-43	21715-21717	df	_
112-44	21718-21719	=	_
112-45	21720-21726	4.9872	_
112-46	21727-21728	;	_
112-47	21729-21732	100	_
112-48	21733-21738	ng/ml	_
112-49	21739-21740	,	_
112-50	21741-21742	t	_
112-51	21743-21744	=	_
112-52	21745-21751	−2.349	_
112-53	21752-21753	,	_
112-54	21754-21756	df	_
112-55	21757-21758	=	_
112-56	21759-21765	4.1296	_
112-57	21766-21767	;	_
112-58	21768-21771	Day	_
112-59	21772-21773	3	_
112-60	21774-21775	,	_
112-61	21776-21778	10	_
112-62	21779-21784	ng/ml	_
112-63	21785-21786	,	_
112-64	21787-21788	t	_
112-65	21789-21790	=	_
112-66	21791-21798	−2.8481	_
112-67	21799-21800	,	_
112-68	21801-21803	df	_
112-69	21804-21805	=	_
112-70	21806-21812	6.9658	_
112-71	21813-21814	;	_
112-72	21815-21818	100	_
112-73	21819-21824	ng/ml	_
112-74	21825-21826	,	_
112-75	21827-21828	t	_
112-76	21829-21830	=	_
112-77	21831-21838	−6.3786	_
112-78	21839-21840	,	_
112-79	21841-21843	df	_
112-80	21844-21845	=	_
112-81	21846-21852	3.3998	_
112-82	21853-21854	;	_
112-83	21855-21858	Day	_
112-84	21859-21860	4	_
112-85	21861-21862	,	_
112-86	21863-21866	100	_
112-87	21867-21872	ng/ml	_
112-88	21873-21874	,	_
112-89	21875-21876	t	_
112-90	21877-21878	=	_
112-91	21879-21886	−9.0836	_
112-92	21887-21888	,	_
112-93	21889-21891	df	_
112-94	21892-21893	=	_
112-95	21894-21901	6.9835.	_
112-96	21902-21907	vAChT	_
112-97	21908-21909	,	_
112-98	21910-21913	Day	_
112-99	21914-21915	2	_
112-100	21916-21917	,	_
112-101	21918-21919	t	_
112-102	21920-21921	=	_
112-103	21922-21928	5.9222	_
112-104	21929-21930	,	_
112-105	21931-21933	df	_
112-106	21934-21935	=	_
112-107	21936-21942	5.3619	_
112-108	21943-21944	;	_
112-109	21945-21948	Day	_
112-110	21949-21950	4	_
112-111	21951-21952	,	_
112-112	21953-21954	t	_
112-113	21955-21956	=	_
112-114	21957-21963	7.1016	_
112-115	21964-21965	,	_
112-116	21966-21968	df	_
112-117	21969-21970	=	_
112-118	21971-21977	4.8784	_
112-119	21978-21979	.	_

113-1	21980-21986	Number	_
113-2	21987-21989	of	_
113-3	21990-22000	biological	_
113-4	22001-22011	replicates	_
113-5	22012-22013	:	_
113-6	22014-22016	4.	_
113-7	22017-22021	qPCR	_
113-8	22022-22024	of	_
113-9	22025-22029	ChAT	_
113-10	22030-22034	mRNA	_
113-11	22035-22042	against	_
113-12	22043-22055	housekeeping	_
113-13	22056-22058	in	_
113-14	22059-22065	LA-N-5	_
113-15	22066-22067	,	_
113-16	22068-22069	p	_
113-17	22070-22076	values	_
113-18	22077-22080	are	_
113-19	22081-22086	found	_
113-20	22087-22089	in	_
113-21	22090-22096	Figure	_
113-22	22097-22099	S2	_
113-23	22100-22106	legend	_
113-24	22107-22108	(	_
113-25	22109-22114	Welch	_
113-26	22115-22125	two-sample	_
113-27	22126-22127	t	_
113-28	22128-22132	test	_
113-29	22133-22134	)	_
113-30	22135-22136	:	_
113-31	22137-22140	Day	_
113-32	22141-22142	2	_
113-33	22143-22144	,	_
113-34	22145-22147	10	_
113-35	22148-22153	ng/ml	_
113-36	22154-22155	,	_
113-37	22156-22157	t	_
113-38	22158-22159	=	_
113-39	22160-22167	−4.5204	_
113-40	22168-22169	,	_
113-41	22170-22172	df	_
113-42	22173-22174	=	_
113-43	22175-22180	3.059	_
113-44	22181-22182	;	_
113-45	22183-22186	Day	_
113-46	22187-22188	4	_
113-47	22189-22190	,	_
113-48	22191-22193	10	_
113-49	22194-22199	ng/ml	_
113-50	22200-22201	,	_
113-51	22202-22203	t	_
113-52	22204-22205	=	_
113-53	22206-22213	−4.7639	_
113-54	22214-22215	,	_
113-55	22216-22218	df	_
113-56	22219-22220	=	_
113-57	22221-22227	5.0369	_
113-58	22228-22229	;	_
113-59	22230-22233	100	_
113-60	22234-22239	ng/ml	_
113-61	22240-22241	,	_
113-62	22242-22243	t	_
113-63	22244-22245	=	_
113-64	22246-22253	−4.9161	_
113-65	22254-22255	,	_
113-66	22256-22258	df	_
113-67	22259-22260	=	_
113-68	22261-22267	2.0262	_
113-69	22268-22269	.	_

114-1	22270-22276	Number	_
114-2	22277-22279	of	_
114-3	22280-22290	biological	_
114-4	22291-22301	replicates	_
114-5	22302-22303	:	_
114-6	22304-22305	4	_
114-7	22306-22307	.	_

115-1	22308-22312	Mean	_
115-2	22313-22321	absolute	_
115-3	22322-22334	count-change	_
115-4	22335-22341	LA-N-5	_
115-5	22342-22348	versus	_
115-6	22349-22355	LA-N-2	_
115-7	22356-22357	,	_
115-8	22358-22362	text	_
115-9	22363-22365	of	_
115-10	22366-22372	Figure	_
115-11	22373-22374	3	_
115-12	22375-22376	(	_
115-13	22377-22382	Welch	_
115-14	22383-22393	two-sample	_
115-15	22394-22395	t	_
115-16	22396-22400	test	_
115-17	22401-22402	)	_
115-18	22403-22404	:	_
115-19	22405-22406	t	_
115-20	22407-22408	=	_
115-21	22409-22415	2.6183	_
115-22	22416-22417	,	_
115-23	22418-22420	df	_
115-24	22421-22422	=	_
115-25	22423-22427	1108	_
115-26	22428-22429	.	_

116-1	22430-22436	Number	_
116-2	22437-22439	of	_
116-3	22440-22448	compared	_
116-4	22449-22453	miRs	_
116-5	22454-22455	:	_
116-6	22456-22459	490	_
116-7	22460-22461	.	_

117-1	22462-22468	Target	_
117-2	22469-22474	count	_
117-3	22475-22477	of	_
117-4	22478-22486	families	_
117-5	22487-22488	,	_
117-6	22489-22495	Figure	_
117-7	22496-22498	5A	_
117-8	22499-22500	:	_
117-9	22501-22509	enriched	_
117-10	22510-22512	in	_
117-11	22513-22517	both	_
117-12	22518-22524	versus	_
117-13	22525-22533	enriched	_
117-14	22534-22536	in	_
117-15	22537-22540	one	_
117-16	22541-22545	cell	_
117-17	22546-22547	,	_
117-18	22548-22549	t	_
117-19	22550-22551	=	_
117-20	22552-22558	3.1831	_
117-21	22559-22560	,	_
117-22	22561-22563	df	_
117-23	22564-22565	=	_
117-24	22566-22568	73	_
117-25	22569-22570	;	_
117-26	22571-22579	enriched	_
117-27	22580-22582	in	_
117-28	22583-22589	mir-10	_
117-29	22590-22596	versus	_
117-30	22597-22605	enriched	_
117-31	22606-22608	in	_
117-32	22609-22614	other	_
117-33	22615-22630	sex-independent	_
117-34	22631-22639	families	_
117-35	22640-22641	,	_
117-36	22642-22643	t	_
117-37	22644-22645	=	_
117-38	22646-22651	−3.28	_
117-39	22652-22653	,	_
117-40	22654-22656	df	_
117-41	22657-22658	=	_
117-42	22659-22665	7.1879	_
117-43	22666-22667	.	_

118-1	22668-22674	Number	_
118-2	22675-22677	of	_
118-3	22678-22686	compared	_
118-4	22687-22695	families	_
118-5	22696-22697	:	_
118-6	22698-22700	17	_
118-7	22701-22702	(	_
118-8	22703-22704	5	_
118-9	22705-22711	versus	_
118-10	22712-22714	12	_
118-11	22715-22716	)	_
118-12	22717-22718	.	_

119-1	22719-22729	Validation	_
119-2	22730-22732	of	_
119-3	22733-22744	miR-125b-5p	_
119-4	22745-22754	targeting	_
119-5	22755-22757	of	_
119-6	22758-22762	AChE	_
119-7	22763-22764	,	_
119-8	22765-22766	p	_
119-9	22767-22773	values	_
119-10	22774-22777	are	_
119-11	22778-22783	found	_
119-12	22784-22786	in	_
119-13	22787-22794	Results	_
119-14	22795-22796	(	_
119-15	22797-22804	one-way	_
119-16	22805-22810	ANOVA	_
119-17	22811-22812	)	_
119-18	22813-22814	:	_
119-19	22815-22821	Figure	_
119-20	22822-22824	6B	_
119-21	22825-22826	,	_
119-22	22827-22828	n	_
119-23	22829-22830	=	_
119-24	22831-22832	4	_
119-25	22833-22834	,	_
119-26	22835-22842	f-ratio	_
119-27	22843-22848	value	_
119-28	22849-22856	9.19882	_
119-29	22857-22858	,	_
119-30	22859-22861	df	_
119-31	22862-22869	between	_
119-32	22870-22880	treatments	_
119-33	22881-22882	2	_
119-34	22883-22884	,	_
119-35	22885-22891	within	_
119-36	22892-22902	treatments	_
119-37	22903-22904	9	_
119-38	22905-22906	;	_
119-39	22907-22913	Figure	_
119-40	22914-22916	6C	_
119-41	22917-22918	,	_
119-42	22919-22926	control	_
119-43	22927-22928	n	_
119-44	22929-22930	=	_
119-45	22931-22932	5	_
119-46	22933-22934	,	_
119-47	22935-22939	125b	_
119-48	22940-22941	n	_
119-49	22942-22943	=	_
119-50	22944-22945	4	_
119-51	22946-22947	,	_
119-52	22948-22951	132	_
119-53	22952-22953	n	_
119-54	22954-22955	=	_
119-55	22956-22957	3	_
119-56	22958-22959	,	_
119-57	22960-22967	f-ratio	_
119-58	22968-22973	value	_
119-59	22974-22982	11.59814	_
119-60	22983-22984	,	_
119-61	22985-22987	df	_
119-62	22988-22995	between	_
119-63	22996-23006	treatments	_
119-64	23007-23008	2	_
119-65	23009-23010	,	_
119-66	23011-23017	within	_
119-67	23018-23028	treatments	_
119-68	23029-23030	8	_
119-69	23031-23032	.	_

120-1	23033-23034	N	_
120-2	23035-23041	refers	_
120-3	23042-23044	to	_
120-4	23045-23055	biological	_
120-5	23056-23066	replicates	_
120-6	23067-23068	.	_

121-1	23069-23073	Data	_
121-2	23074-23077	and	_
121-3	23078-23082	Code	_
121-4	23083-23095	Availability	_
121-5	23096-23099	The	_
121-6	23100-23104	code	_
121-7	23105-23108	and	_
121-8	23109-23119	additional	_
121-9	23120-23133	supplementary	_
121-10	23134-23143	materials	_
121-11	23144-23153	generated	_
121-12	23154-23160	during	_
121-13	23161-23165	this	_
121-14	23166-23171	study	_
121-15	23172-23175	are	_
121-16	23176-23185	available	_
121-17	23186-23188	at	_
121-18	23189-23194	https	_
121-19	23195-23196	:	_
121-20	23197-23250	//github.com/slobentanzer/integrative-transcriptomics	_
121-21	23251-23252	.	_

122-1	23253-23256	The	_
122-2	23257-23267	sequencing	_
122-3	23268-23276	datasets	_
122-4	23277-23286	generated	_
122-5	23287-23293	during	_
122-6	23294-23298	this	_
122-7	23299-23304	study	_
122-8	23305-23308	are	_
122-9	23309-23318	available	_
122-10	23319-23321	at	_
122-11	23322-23326	NCBI	_
122-12	23327-23330	GEO	_
122-13	23331-23332	:	_
122-14	23333-23342	GSE120520	_
122-15	23343-23346	and	_
122-16	23347-23356	GSE132951	_
122-17	23357-23358	.	_

123-1	23359-23371	Accompanying	_
123-2	23372-23379	website	_
123-3	23380-23381	:	_
123-4	23382-23387	https	_
123-5	23388-23389	:	_
123-6	23390-23436	//slobentanzer.github.io/cholinergic-neurokine	_

